falseQ30001355790--12-31http://fasb.org/us-gaap/2026#RelatedPartyMemberhttp://fasb.org/us-gaap/2026#RelatedPartyMemberhttp://fasb.org/us-gaap/2026#ProductMemberhttp://fasb.org/us-gaap/2026#ProductMemberhttp://fasb.org/us-gaap/2026#ProductMemberhttp://fasb.org/us-gaap/2026#ProductMember3http://fasb.org/us-gaap/2026#ProductMemberhttp://fasb.org/us-gaap/2026#ProductMemberhttp://fasb.org/us-gaap/2026#ProductMemberhttp://fasb.org/us-gaap/2026#ProductMemberhttp://fasb.org/us-gaap/2026#ProductMemberhttp://fasb.org/us-gaap/2026#ProductMemberhttp://fasb.org/us-gaap/2026#ProductMemberhttp://fasb.org/us-gaap/2026#ProductMemberhttp://fasb.org/us-gaap/2026#ProductMemberhttp://fasb.org/us-gaap/2026#ProductMemberhttp://fasb.org/us-gaap/2026#ProductMemberhttp://fasb.org/us-gaap/2026#ProductMember0001355790isco:SeriesITwoPreferredStockMember2026-09-300001355790us-gaap:PreferredStockMember2025-09-300001355790isco:SeriesBSeriesGSeriesITwoPreferredStockMember2026-09-300001355790us-gaap:AdditionalPaidInCapitalMember2026-03-310001355790us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberisco:SaleOfLifelineCellTechnologyLLCMember2025-12-310001355790us-gaap:LeaseholdImprovementsMember2025-12-310001355790srt:MinimumMember2026-09-300001355790isco:TwoZeroOneZeroPlanMember2020-06-012020-06-300001355790isco:SanDiegoMemberisco:CorporateHeadquartersMember2025-02-012025-02-280001355790us-gaap:AdditionalPaidInCapitalMember2026-06-300001355790us-gaap:RedeemableConvertiblePreferredStockMember2026-07-012026-09-300001355790us-gaap:AdditionalPaidInCapitalMember2026-09-300001355790isco:TherapeuticMarketMember2025-01-012025-09-300001355790isco:ComputerEquipmentAndSoftwareMember2025-12-310001355790isco:UnsecuredNonConvertiblePromissoryNoteMember2023-01-012023-12-3100013557902025-09-3000013557902026-11-200001355790us-gaap:EmployeeStockOptionMember2025-01-012025-09-300001355790us-gaap:SeriesGPreferredStockMember2026-09-3000013557902025-01-012025-01-310001355790us-gaap:CommonStockMember2026-03-310001355790isco:UnsecuredNonConvertiblePromissoryNoteMember2025-09-300001355790isco:SeriesDRedeemableConvertiblePreferredStockMember2026-09-300001355790isco:TwoZeroOneZeroPlanMember2026-01-012026-09-300001355790us-gaap:RetainedEarningsMember2025-01-012025-03-310001355790srt:MinimumMemberisco:TwoZeroOneZeroPlanMember2023-09-012023-09-300001355790us-gaap:CommonStockMember2025-06-3000013557902025-01-012025-03-310001355790us-gaap:PreferredStockMember2026-06-300001355790us-gaap:RedeemableConvertiblePreferredStockMember2026-01-012026-09-300001355790us-gaap:PreferredStockMember2026-03-310001355790us-gaap:SeriesBPreferredStockMember2026-09-300001355790srt:MaximumMemberisco:TwoZeroOneZeroPlanMember2010-04-300001355790isco:SanDiegoMemberisco:SupplementalOfficeSpaceMember2025-01-012025-01-310001355790us-gaap:MachineryAndEquipmentMember2026-09-3000013557902025-01-012025-09-300001355790us-gaap:RetainedEarningsMember2025-12-310001355790us-gaap:RedeemableConvertiblePreferredStockMember2026-09-300001355790isco:SanDiegoMemberisco:SupplementalOfficeSpaceMember2026-01-012026-09-300001355790us-gaap:PreferredStockMember2025-03-310001355790us-gaap:EmployeeStockOptionMember2025-07-012025-09-300001355790us-gaap:NonredeemableConvertiblePreferredStockMember2025-07-012025-09-300001355790us-gaap:EmployeeStockOptionMember2026-01-012026-09-300001355790us-gaap:AdditionalPaidInCapitalMember2026-04-012026-06-300001355790srt:MaximumMember2026-09-300001355790us-gaap:EmployeeStockOptionMember2026-01-012026-09-300001355790isco:AntiAgingMarketMember2025-07-012025-09-3000013557902025-12-310001355790us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-09-300001355790isco:AntiAgingSkincareMarketMember2026-07-012026-09-300001355790isco:TwoZeroOneZeroPlanMember2025-12-310001355790us-gaap:ConstructionInProgressMember2025-12-310001355790us-gaap:RetainedEarningsMember2026-06-300001355790isco:SeriesDRedeemableConvertiblePreferredStockMember2025-09-300001355790us-gaap:CommonStockMember2025-09-300001355790isco:SanDiegoMemberisco:CorporateHeadquartersMember2021-10-012021-10-310001355790isco:OptionsOutstandingMember2026-09-300001355790us-gaap:MachineryAndEquipmentMember2025-12-310001355790us-gaap:PreferredStockMember2025-12-310001355790us-gaap:GeneralAndAdministrativeExpense2026-07-012026-09-300001355790isco:SanDiegoMember2021-10-012021-10-3100013557902026-09-300001355790isco:TherapeuticMarketMember2026-07-012026-09-300001355790us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberisco:TransitionServicesAgreementMember2026-07-012026-09-300001355790us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-09-300001355790isco:UnsecuredNonConvertiblePromissoryNoteMember2025-06-300001355790us-gaap:RetainedEarningsMember2024-12-310001355790us-gaap:ResearchAndDevelopmentExpense2026-01-012026-09-300001355790us-gaap:RedeemableConvertiblePreferredStockMember2025-01-012025-09-300001355790isco:UnsecuredNonConvertiblePromissoryNoteMember2025-06-012025-06-300001355790isco:ChiefExecutiveOfficerAndCoChairmanMemberisco:UnsecuredNonConvertiblePromissoryNoteMember2018-03-012022-09-300001355790srt:MaximumMemberisco:TwoZeroOneZeroPlanMember2023-09-300001355790us-gaap:ResearchAndDevelopmentExpense2025-07-012025-09-300001355790us-gaap:CommonStockMember2026-09-3000013557902024-12-310001355790us-gaap:SubsequentEventMember2026-11-200001355790us-gaap:AustralianTaxationOfficeMember2026-01-012026-09-300001355790us-gaap:EmployeeStockOptionMember2025-01-012025-09-300001355790us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMember2025-07-012025-09-300001355790isco:SeriesDRedeemableConvertiblePreferredStockMember2025-12-310001355790isco:AntiAgingSkincareMarketMember2025-07-012025-09-300001355790srt:MinimumMemberisco:UnsecuredNonConvertiblePromissoryNoteMember2024-09-012024-09-300001355790isco:SeriesDRedeemableConvertiblePreferredStockMember2026-06-300001355790isco:AntiAgingSkincareMarketMember2025-01-012025-09-3000013557902026-01-012026-09-300001355790us-gaap:SeriesGPreferredStockMember2025-12-310001355790us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberisco:SaleOfLifelineCellTechnologyLLCMember2025-07-012025-09-300001355790us-gaap:ResearchAndDevelopmentExpense2025-01-012025-09-300001355790us-gaap:EmployeeStockOptionMember2026-07-012026-09-300001355790us-gaap:SeriesGPreferredStockMembersrt:MinimumMember2026-09-300001355790us-gaap:SeriesGPreferredStockMember2026-01-012026-09-300001355790us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberisco:TransitionServicesAgreementMember2026-01-012026-09-300001355790isco:SeriesDRedeemableConvertiblePreferredStockMember2024-12-310001355790us-gaap:EmployeeStockOptionMember2026-07-012026-09-3000013557902026-01-012026-03-310001355790isco:ChiefExecutiveOfficerAndCoChairmanMemberisco:UnsecuredNonConvertiblePromissoryNoteMember2024-09-012024-09-300001355790us-gaap:SeriesBPreferredStockMember2025-12-3100013557902025-06-300001355790us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberisco:SaleOfLifelineCellTechnologyLLCMember2026-09-010001355790isco:SeriesBSeriesGSeriesIOneSeriesITwoPreferredStockMember2025-12-310001355790us-gaap:RetainedEarningsMember2026-09-300001355790srt:ExecutiveOfficerMemberus-gaap:SubsequentEventMember2026-10-202026-10-200001355790isco:SeriesITwoConvertiblePreferredStockMember2026-01-012026-09-300001355790isco:ComputerEquipmentAndSoftwareMember2026-09-300001355790us-gaap:OfficeEquipmentMember2026-09-3000013557902025-04-012025-06-300001355790isco:UnsecuredNonConvertiblePromissoryNoteMember2022-09-300001355790isco:TherapeuticMarketMember2026-01-012026-09-300001355790isco:UnsecuredNonConvertiblePromissoryNoteMember2026-01-012026-09-300001355790isco:SeriesDRedeemableConvertiblePreferredStockMember2026-03-3100013557902025-07-012025-09-300001355790us-gaap:CommonStockMember2025-03-310001355790us-gaap:RetainedEarningsMember2025-04-012025-06-300001355790srt:MaximumMemberisco:TwoZeroOneZeroPlanMember2023-09-012023-09-300001355790us-gaap:AdditionalPaidInCapitalMember2026-07-012026-09-300001355790isco:UnsecuredNonConvertiblePromissoryNoteMember2026-09-3000013557902026-07-012026-09-300001355790us-gaap:ConstructionInProgressMember2026-09-300001355790isco:AntiAgingMarketMember2025-01-012025-09-300001355790us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMember2026-07-012026-09-300001355790isco:SaleOfLifelineCellTechnologyLLCMember2026-07-100001355790us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-09-300001355790isco:SanDiegoMemberisco:CorporateHeadquartersMember2026-01-012026-09-300001355790us-gaap:GeneralAndAdministrativeExpense2025-07-012025-09-300001355790isco:UnsecuredNonConvertiblePromissoryNoteMember2023-12-310001355790us-gaap:RetainedEarningsMember2026-01-012026-03-310001355790isco:UnsecuredNonConvertiblePromissoryNoteMember2026-02-012026-02-280001355790isco:ChiefExecutiveOfficerAndCoChairmanMemberisco:UnsecuredNonConvertiblePromissoryNoteMember2023-01-012023-12-310001355790us-gaap:CommonStockMember2026-06-300001355790us-gaap:RetainedEarningsMember2026-07-012026-09-300001355790us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberisco:SaleOfLifelineCellTechnologyLLCMember2026-07-100001355790us-gaap:LeaseholdImprovementsMember2026-09-300001355790us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberisco:SaleOfLifelineCellTechnologyLLCMember2026-07-012026-09-300001355790srt:MaximumMember2026-01-012026-09-300001355790srt:MinimumMemberisco:TwoZeroOneZeroPlanMember2023-09-300001355790isco:TherapeuticMarketMember2025-07-012025-09-300001355790isco:TwoZeroOneZeroPlanMember2026-09-300001355790us-gaap:RestrictedStockUnitsRSUMember2026-07-012026-09-300001355790us-gaap:CommonStockMember2025-12-310001355790us-gaap:SeriesDPreferredStockMember2026-01-012026-09-300001355790isco:ChiefExecutiveOfficerAndCoChairmanMemberisco:UnsecuredNonConvertiblePromissoryNoteMember2025-09-012025-09-300001355790us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberisco:SaleOfLifelineCellTechnologyLLCMember2025-01-012025-09-300001355790us-gaap:SeriesDPreferredStockMembersrt:MinimumMember2026-09-300001355790isco:SanDiegoMemberisco:SupplementalOfficeSpaceMember2021-11-300001355790us-gaap:NonredeemableConvertiblePreferredStockMember2025-01-012025-09-300001355790us-gaap:RetainedEarningsMember2026-03-310001355790us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001355790isco:UnsecuredNonConvertiblePromissoryNoteMember2026-02-280001355790us-gaap:CommonStockMember2024-12-310001355790us-gaap:PreferredStockMember2026-09-300001355790isco:SeriesDRedeemableConvertiblePreferredStockMember2025-06-300001355790us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberisco:SaleOfLifelineCellTechnologyLLCMember2026-01-012026-09-300001355790us-gaap:PreferredStockMember2025-06-300001355790us-gaap:RedeemableConvertiblePreferredStockMember2025-07-012025-09-300001355790isco:UnsecuredNonConvertiblePromissoryNoteMember2024-09-012024-09-300001355790us-gaap:AdditionalPaidInCapitalMember2025-12-310001355790isco:AntiAgingMarketMember2026-07-012026-09-300001355790isco:SeriesDRedeemableConvertiblePreferredStockMember2025-03-3100013557902026-06-300001355790us-gaap:RetainedEarningsMember2026-04-012026-06-300001355790us-gaap:SeriesDPreferredStockMember2026-09-300001355790us-gaap:PreferredStockMember2024-12-310001355790us-gaap:NonredeemableConvertiblePreferredStockMember2025-12-310001355790us-gaap:GeneralAndAdministrativeExpense2026-01-012026-09-300001355790us-gaap:NonredeemableConvertiblePreferredStockMember2026-07-012026-09-300001355790isco:SeriesBSeriesGSeriesIOneSeriesITwoPreferredStockMember2026-09-3000013557902026-04-012026-06-300001355790us-gaap:CommonStockMemberisco:TwoThousandTenEquityParticipationPlanMember2026-09-300001355790isco:ChiefExecutiveOfficerAndCoChairmanMemberisco:UnsecuredNonConvertiblePromissoryNoteMember2022-09-300001355790us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberisco:SaleOfLifelineCellTechnologyLLCMember2026-09-012026-09-010001355790us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300001355790us-gaap:AdditionalPaidInCapitalMember2025-09-300001355790us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-12-310001355790isco:UnsecuredNonConvertiblePromissoryNoteMember2026-09-012026-09-300001355790isco:UnsecuredNonConvertiblePromissoryNoteMember2024-09-300001355790isco:SeriesBSeriesGSeriesITwoPreferredStockMember2025-12-310001355790isco:AntiAgingSkincareMarketMember2026-01-012026-09-300001355790us-gaap:NonredeemableConvertiblePreferredStockMember2026-09-300001355790isco:SeriesITwoPreferredStockMember2025-12-310001355790us-gaap:RetainedEarningsMember2025-07-012025-09-300001355790us-gaap:OfficeEquipmentMember2025-12-310001355790isco:AntiAgingMarketMember2026-01-012026-09-300001355790us-gaap:RetainedEarningsMember2025-06-300001355790us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-3100013557902026-03-310001355790us-gaap:AdditionalPaidInCapitalMember2025-06-300001355790us-gaap:RestrictedStockUnitsRSUMember2026-09-300001355790isco:SanDiegoMemberisco:SupplementalOfficeSpaceMember2021-11-012021-11-300001355790us-gaap:RelatedPartyMember2026-09-300001355790us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-09-300001355790us-gaap:CommonStockMember2026-07-012026-09-300001355790us-gaap:AdditionalPaidInCapitalMember2024-12-310001355790us-gaap:NonredeemableConvertiblePreferredStockMember2026-01-012026-09-300001355790isco:SanDiegoMemberisco:SupplementalOfficeSpaceMember2025-01-310001355790us-gaap:GeneralAndAdministrativeExpense2025-01-012025-09-300001355790us-gaap:RelatedPartyMember2026-09-300001355790us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300001355790srt:MaximumMemberisco:UnsecuredNonConvertiblePromissoryNoteMember2024-09-012024-09-300001355790us-gaap:EmployeeStockOptionMember2025-07-012025-09-3000013557902021-12-152021-12-150001355790us-gaap:RetainedEarningsMember2025-03-310001355790us-gaap:AdditionalPaidInCapitalMember2025-03-310001355790us-gaap:ResearchAndDevelopmentExpense2026-07-012026-09-3000013557902025-03-310001355790us-gaap:RetainedEarningsMember2025-09-30isco:Customerxbrli:purexbrli:sharesisco:Segmentisco:Directorsiso4217:USDisco:Lease
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
|
|
☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2026
or
|
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from __________ to __________
Commission File Number: 0-51891
INTERNATIONAL STEM CELL CORPORATION
(Exact name of registrant as specified in its charter)
|
|
|
Delaware |
|
20-4494098 |
(State or other jurisdiction of incorporation or organization) |
|
(I.R.S. Employer Identification No.) |
9745 Businesspark Ave San Diego, CA |
|
92131 |
(Address of principal executive offices) |
|
(Zip Code) |
(760) 940-6383
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
None |
|
None |
|
None |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
|
|
|
|
|
|
|
Emerging growth company |
|
☐ |
If an emerging growth company, indicate by check mark if the registrant elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of November 20, 2026, the Registrant had 8,163,389 shares of Common Stock outstanding.
International Stem Cell Corporation and Subsidiaries
Form 10-Q
Table of Contents
PART I – FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements
International Stem Cell Corporation and Subsidiaries
Condensed Consolidated Balance Sheets
(In thousands, except share and par value data)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
|
December 31, |
|
|
|
2026 |
|
|
2025 |
|
Assets |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash |
|
$ |
20,033 |
|
|
$ |
793 |
|
Accounts receivable, net |
|
|
5 |
|
|
|
5 |
|
Escrow receivable |
|
|
2,600 |
|
|
|
— |
|
Inventories |
|
|
110 |
|
|
|
100 |
|
Prepaid expenses and other current assets |
|
|
108 |
|
|
|
166 |
|
Current assets of discontinued operations (Note 10) |
|
|
— |
|
|
|
2,347 |
|
Total current assets |
|
|
22,856 |
|
|
|
3,411 |
|
Non-current inventories |
|
|
10 |
|
|
|
7 |
|
Property and equipment, net |
|
|
19 |
|
|
|
21 |
|
Intangible assets, net |
|
|
484 |
|
|
|
630 |
|
Right-of-use assets |
|
|
36 |
|
|
|
154 |
|
Deposits and other assets |
|
|
14 |
|
|
|
14 |
|
Non-current assets of discontinued operations (Note 10) |
|
|
— |
|
|
|
582 |
|
Total assets |
|
$ |
23,419 |
|
|
$ |
4,819 |
|
Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Accounts payable |
|
$ |
810 |
|
|
$ |
109 |
|
Accrued liabilities |
|
|
374 |
|
|
|
305 |
|
Operating lease liabilities, current |
|
|
39 |
|
|
|
166 |
|
Other current liabilities |
|
|
40 |
|
|
|
— |
|
Advances |
|
|
250 |
|
|
|
250 |
|
Related party note payable |
|
|
— |
|
|
|
3,340 |
|
Current liabilities of discontinued operations (Note 10) |
|
|
— |
|
|
|
409 |
|
Total current liabilities |
|
|
1,513 |
|
|
|
4,579 |
|
Operating lease liabilities, net of current portion |
|
|
— |
|
|
|
— |
|
Non-current liabilities of discontinued operations (Note 10) |
|
|
— |
|
|
|
— |
|
Total liabilities |
|
|
1,513 |
|
|
|
4,579 |
|
Commitments and contingencies (Note 8) |
|
|
|
|
|
|
Series D redeemable convertible preferred stock, $0.001 par value; 50 shares authorized; 43 shares issued and outstanding; liquidation preference of $4,300 at September 30, 2026 and December 31, 2025 |
|
|
4,300 |
|
|
|
4,300 |
|
Stockholders' Equity (Deficit): |
|
|
|
|
|
|
Non-redeemable convertible preferred stock, $0.001 par value; 10,004,310 and 10,004,310 shares authorized; 5,254,310 and 5,254,310 shares issued and outstanding; liquidation preference of $9,838 and $9,826 at September 30, 2026 and December 31, 2025, respectively |
|
|
5 |
|
|
|
5 |
|
Common stock, $0.001 par value; 120,000,000 shares authorized; 8,163,389 and 8,004,389 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively |
|
|
8 |
|
|
|
8 |
|
Additional paid-in capital |
|
|
107,209 |
|
|
|
107,030 |
|
Accumulated deficit |
|
|
(89,616 |
) |
|
|
(111,103 |
) |
Total stockholders' equity (deficit) |
|
|
17,606 |
|
|
|
(4,060 |
) |
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) |
|
$ |
23,419 |
|
|
$ |
4,819 |
|
See accompanying notes to the unaudited condensed consolidated financial statements.
International Stem Cell Corporation and Subsidiaries
Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Product sales |
|
$ |
147 |
|
|
$ |
165 |
|
|
$ |
444 |
|
|
$ |
443 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales |
|
|
71 |
|
|
|
37 |
|
|
|
142 |
|
|
|
147 |
|
General and administrative |
|
|
707 |
|
|
|
602 |
|
|
|
2,132 |
|
|
|
1,974 |
|
Selling and marketing |
|
|
84 |
|
|
|
100 |
|
|
|
271 |
|
|
|
295 |
|
Research and development |
|
|
106 |
|
|
|
80 |
|
|
|
270 |
|
|
|
294 |
|
Total operating expenses |
|
|
968 |
|
|
|
819 |
|
|
|
2,815 |
|
|
|
2,710 |
|
Loss from operations |
|
|
(821 |
) |
|
|
(654 |
) |
|
|
(2,371 |
) |
|
|
(2,267 |
) |
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
|
(2 |
) |
|
|
(1 |
) |
|
|
(5 |
) |
|
|
(6 |
) |
Interest expense - related party |
|
|
(27 |
) |
|
|
(36 |
) |
|
|
(93 |
) |
|
|
(110 |
) |
Other income |
|
|
1 |
|
|
|
— |
|
|
|
4 |
|
|
|
— |
|
Total other expense, net |
|
|
(28 |
) |
|
|
(37 |
) |
|
|
(94 |
) |
|
|
(116 |
) |
Net loss from continuing operations |
|
|
(849 |
) |
|
|
(691 |
) |
|
|
(2,465 |
) |
|
|
(2,383 |
) |
Net income from discontinued operations, net of tax (Note 10) |
|
|
22,627 |
|
|
|
748 |
|
|
|
23,952 |
|
|
|
2,313 |
|
Net income (loss) |
|
|
21,778 |
|
|
|
57 |
|
|
|
21,487 |
|
|
|
(70 |
) |
Undistributed earnings allocated to participating securities |
|
|
(10,532 |
) |
|
|
(28 |
) |
|
|
(10,403 |
) |
|
|
— |
|
Net income (loss) allocable to common stockholders |
|
$ |
11,246 |
|
|
$ |
29 |
|
|
$ |
11,084 |
|
|
$ |
(70 |
) |
Net income (loss) per common share |
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations - basic and diluted |
|
$ |
(0.11 |
) |
|
$ |
(0.09 |
) |
|
$ |
(0.31 |
) |
|
$ |
(0.30 |
) |
Discontinued operations - basic and diluted |
|
$ |
1.51 |
|
|
$ |
0.09 |
|
|
$ |
1.69 |
|
|
$ |
0.29 |
|
Total net income (loss) per common share - basic and diluted |
|
$ |
1.40 |
|
|
$ |
0.00 |
|
|
$ |
1.38 |
|
|
$ |
(0.01 |
) |
Weighted-average common shares used to compute net income (loss) per share, basic and diluted |
|
|
8,028,857 |
|
|
|
8,004,389 |
|
|
|
8,012,485 |
|
|
|
8,004,389 |
|
See accompanying notes to the unaudited condensed consolidated financial statements.
International Stem Cell Corporation and Subsidiaries
Condensed Consolidated Statements of Changes in Redeemable Convertible
Preferred Stock and Stockholders’ Equity (Deficit)
(In thousands)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three and Nine Months Ended September 30, 2026 |
|
|
|
Series D Redeemable |
|
|
|
Non-redeemable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible |
|
|
|
Convertible |
|
|
Common |
|
|
Additional |
|
|
|
|
|
Total |
|
|
|
Preferred Stock |
|
|
|
Preferred Stock |
|
|
Stock |
|
|
Paid-in |
|
|
Accumulated |
|
|
Stockholders' |
|
|
|
Shares |
|
|
Amount |
|
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Deficit |
|
|
Equity (Deficit) |
|
Balance at December 31, 2025 |
|
|
— |
|
|
$ |
4,300 |
|
|
|
|
5,254 |
|
|
$ |
5 |
|
|
|
8,004 |
|
|
$ |
8 |
|
|
$ |
107,030 |
|
|
$ |
(111,103 |
) |
|
$ |
(4,060 |
) |
Stock-based compensation |
|
|
— |
|
|
|
— |
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
64 |
|
|
|
— |
|
|
|
64 |
|
Net loss |
|
|
— |
|
|
|
— |
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(220 |
) |
|
|
(220 |
) |
Balance at March 31, 2026 |
|
|
— |
|
|
|
4,300 |
|
|
|
|
5,254 |
|
|
|
5 |
|
|
|
8,004 |
|
|
|
8 |
|
|
|
107,094 |
|
|
|
(111,323 |
) |
|
|
(4,216 |
) |
Stock-based compensation |
|
|
— |
|
|
|
— |
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
59 |
|
|
|
— |
|
|
|
59 |
|
Net loss |
|
|
— |
|
|
|
— |
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(71 |
) |
|
|
(71 |
) |
Balance at June 30, 2026 |
|
|
— |
|
|
|
4,300 |
|
|
|
|
5,254 |
|
|
|
5 |
|
|
|
8,004 |
|
|
|
8 |
|
|
|
107,153 |
|
|
|
(111,394 |
) |
|
|
(4,228 |
) |
Stock-based compensation |
|
|
— |
|
|
|
— |
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
35 |
|
|
|
— |
|
|
|
35 |
|
Options exercised |
|
|
— |
|
|
|
— |
|
|
|
|
— |
|
|
|
— |
|
|
|
159 |
|
|
|
— |
|
|
|
21 |
|
|
|
— |
|
|
|
21 |
|
Net income |
|
|
— |
|
|
|
— |
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
21,778 |
|
|
|
21,778 |
|
Balance at September 30, 2026 |
|
|
— |
|
|
$ |
4,300 |
|
|
|
|
5,254 |
|
|
$ |
5 |
|
|
|
8,163 |
|
|
$ |
8 |
|
|
$ |
107,209 |
|
|
$ |
(89,616 |
) |
|
$ |
17,606 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three and Nine Months Ended September 30, 2025 |
|
|
|
Series D Redeemable |
|
|
|
Non-redeemable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible |
|
|
|
Convertible |
|
|
Common |
|
|
Additional |
|
|
|
|
|
Total |
|
|
|
Preferred Stock |
|
|
|
Preferred Stock |
|
|
Stock |
|
|
Paid-in |
|
|
Accumulated |
|
|
Stockholders' |
|
|
|
Shares |
|
|
Amount |
|
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Deficit |
|
|
Deficit |
|
Balance at December 31, 2024 |
|
|
— |
|
|
$ |
4,300 |
|
|
|
|
5,254 |
|
|
$ |
5 |
|
|
|
8,004 |
|
|
$ |
8 |
|
|
$ |
106,742 |
|
|
$ |
(110,685 |
) |
|
$ |
(3,930 |
) |
Stock-based compensation |
|
|
— |
|
|
|
— |
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
100 |
|
|
|
— |
|
|
|
100 |
|
Net loss |
|
|
— |
|
|
|
— |
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(256 |
) |
|
|
(256 |
) |
Balance at March 31, 2025 |
|
|
— |
|
|
|
4,300 |
|
|
|
|
5,254 |
|
|
|
5 |
|
|
|
8,004 |
|
|
|
8 |
|
|
|
106,842 |
|
|
|
(110,941 |
) |
|
|
(4,086 |
) |
Stock-based compensation |
|
|
— |
|
|
|
— |
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
61 |
|
|
|
— |
|
|
|
61 |
|
Net income |
|
|
— |
|
|
|
— |
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
129 |
|
|
|
129 |
|
Balance at June 30, 2025 |
|
|
— |
|
|
|
4,300 |
|
|
|
|
5,254 |
|
|
|
5 |
|
|
|
8,004 |
|
|
|
8 |
|
|
|
106,903 |
|
|
|
(110,812 |
) |
|
|
(3,896 |
) |
Stock-based compensation |
|
|
— |
|
|
|
— |
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
63 |
|
|
|
— |
|
|
|
63 |
|
Net loss |
|
|
— |
|
|
|
— |
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
57 |
|
|
|
57 |
|
Balance at September 30, 2025 |
|
|
— |
|
|
$ |
4,300 |
|
|
|
|
5,254 |
|
|
$ |
5 |
|
|
|
8,004 |
|
|
$ |
8 |
|
|
$ |
106,966 |
|
|
$ |
(110,755 |
) |
|
$ |
(3,776 |
) |
See accompanying notes to the unaudited condensed consolidated financial statements.
International Stem Cell Corporation and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(In thousands) (Unaudited)
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30, |
|
|
|
2026 |
|
|
2025 |
|
Cash flows from operating activities |
|
|
|
|
|
|
Net income (loss) |
|
$ |
21,487 |
|
|
$ |
(70 |
) |
Less: Net income from discontinued operations, net of tax |
|
|
23,952 |
|
|
|
2,313 |
|
Net loss from continuing operations |
|
|
(2,465 |
) |
|
|
(2,383 |
) |
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: |
|
|
|
|
|
|
Stock-based compensation |
|
|
138 |
|
|
|
188 |
|
Depreciation and amortization |
|
|
58 |
|
|
|
62 |
|
Non-cash operating lease expense |
|
|
118 |
|
|
|
107 |
|
Interest expense on related party note payable |
|
|
94 |
|
|
|
110 |
|
Change in inventory reserve |
|
|
10 |
|
|
|
10 |
|
Impairment of intangible assets |
|
|
111 |
|
|
|
— |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
Accounts receivable |
|
|
— |
|
|
|
(4 |
) |
Inventories |
|
|
(23 |
) |
|
|
13 |
|
Prepaid expenses and other current assets |
|
|
58 |
|
|
|
(35 |
) |
Accounts payable |
|
|
701 |
|
|
|
70 |
|
Accrued liabilities |
|
|
69 |
|
|
|
(121 |
) |
Payment of accrued interest on related party note payable |
|
|
(933 |
) |
|
|
— |
|
Operating lease liabilities |
|
|
(127 |
) |
|
|
(111 |
) |
Net cash used in operating activities - continuing operations |
|
|
(2,191 |
) |
|
|
(2,094 |
) |
Net cash provided by operating activities - discontinued operations |
|
|
2,055 |
|
|
|
2,070 |
|
Net cash used in operating activities |
|
|
(136 |
) |
|
|
(24 |
) |
Cash flows from investing activities |
|
|
|
|
|
|
Purchases of property and equipment |
|
|
(10 |
) |
|
|
(11 |
) |
Net proceeds from the sale of business (Note 10) |
|
|
21,698 |
|
|
|
— |
|
Payments for patent licenses |
|
|
(13 |
) |
|
|
(1 |
) |
Net cash provided by (used in) investing activities - continuing operations |
|
|
21,675 |
|
|
|
(12 |
) |
Net cash used in investing activities - discontinued operations |
|
|
(20 |
) |
|
|
(28 |
) |
Net cash provided by (used in) investing activities |
|
|
21,655 |
|
|
|
(40 |
) |
Cash flows from financing activities |
|
|
|
|
|
|
Payments on related party note payable |
|
|
(2,500 |
) |
|
|
(200 |
) |
Proceeds from option exercise |
|
|
21 |
|
|
|
— |
|
Net cash used in financing activities |
|
|
(2,479 |
) |
|
|
(200 |
) |
Net increase (decrease) in cash |
|
|
19,040 |
|
|
|
(264 |
) |
Cash (including cash held in discontinued operations), beginning of period |
|
|
993 |
|
|
|
1,230 |
|
Cash (including cash held in discontinued operations), end of period |
|
$ |
20,033 |
|
|
$ |
966 |
|
Less: Cash held in discontinued operations, beginning of period |
|
|
200 |
|
|
|
550 |
|
Cash (excluding cash held in discontinued operations), beginning of period |
|
$ |
793 |
|
|
$ |
680 |
|
Supplemental disclosure of non-cash operating activities: |
|
|
|
|
|
|
Operating lease right-of-use asset obtained in exchange for operating lease liabilities: |
|
|
|
|
|
|
Continuing operations |
|
$ |
— |
|
|
$ |
93 |
|
Discontinued operations |
|
$ |
— |
|
|
$ |
209 |
|
Supplemental disclosure of non-cash investing activities: |
|
|
|
|
|
|
Escrow receivable |
|
$ |
2,600 |
|
|
$ |
— |
|
Transaction costs payable |
|
$ |
687 |
|
|
$ |
— |
|
Payable to ATCC for the working capital true-up |
|
$ |
40 |
|
|
$ |
— |
|
Supplemental disclosure of cash flow information: |
|
|
|
|
|
|
Cash paid for interest |
|
$ |
933 |
|
|
$ |
5 |
|
See accompanying notes to the unaudited condensed consolidated financial statements.
International Stem Cell Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
1. Description of Business, Basis of Presentation, and Summary of Significant Accounting Policies
Description of Business
International Stem Cell Corporation (“ISCO” or the “Company”) is a clinical-stage biotechnology company headquartered in San Diego, California. It was organized in Delaware in June 2005. ISCO develops stem cell therapies for multiple indications, including diseases of the central nervous system. These therapies are based on human parthenogenetic stem cells (“hpSCs”), a proprietary type of pluripotent stem cell that offers the potential to immune-match tens of millions of patients using a limited number of cell lines. ISCO was the first company to take a pluripotent stem cell-derived therapy for Parkinson’s disease into clinical trials. The Company has the following wholly owned subsidiaries:
•Lifeline Skin Care, Inc. (“LSC”) – develops, manufactures, and markets a category of anti-aging skin care products for the anti-aging market based on the Company’s proprietary parthenogenetic stem cell technology and small molecule technology;
•Cyto Therapeutics Pty. Ltd. (“Cyto Therapeutics”) – performs research and development (“R&D”) for the therapeutic market and is currently conducting clinical trials in Australia for the use of ISC-hpNSC® in the treatment of Parkinson’s disease.
Sale of Lifeline Cell Technology, LLC ("LCT")
On July 10, 2026, the Company entered into a Membership Interest Purchase Agreement (the "MIPA") with American Type Culture Collection, Inc. ("ATCC"), pursuant to which the Company agreed to sell 100% of the membership interests of Lifeline Cell Technology, LLC ("LCT"), its subsidiary engaged in the development, manufacture, and sale of biological materials and reagents for scientific research, to ATCC (the "Transaction").
At closing, the Company received net cash consideration of $23.1 million, recognized $2.6 million of escrow receivable, slightly offset by a known adjustment to working capital, for total net consideration of $25.6 million.
The transaction closed on September 1, 2026. See Note 10 – Discontinued Operations for historical results of the discontinued operations, which previously represented the LCT reporting segment. Unless otherwise indicated, the information in the remaining notes to the condensed consolidated financial statements refers only to the Company's continuing operations for all periods presented.
Following the completion of the sale, the Company now operates the business on the basis of two reporting segments: therapeutic market (“ISCO”) and anti-aging market (“LSC”). Refer to Note 9 – Segments for further discussion.
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) applicable to interim financial statements. Certain information and notes normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules and regulations. The unaudited interim condensed consolidated financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s condensed consolidated financial statements. The operating results for the three and nine months ended September 30, 2026 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2026. The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2025 included in the Company’s annual report on Form 10-K filed with the SEC on March 30, 2026.
Going Concern
In prior periods, the Company disclosed that its recurring losses and negative cash flows from operations raised substantial doubt about its ability to continue as a going concern. On September 1, 2026, the Company completed the sale of LCT and received net cash consideration of $23.1 million (see Note 10 – Discontinued Operations for additional details regarding the sale of LCT). As of the date of this filing, the Company had approximately $17.0 million in cash.
Management evaluated whether conditions and events, considered in the aggregate, raised substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the date these unaudited condensed consolidated financial statements are issued. Based on the proceeds of the sale, management concluded that the conditions that previously raised substantial doubt have been alleviated and that substantial doubt no longer exists. Accordingly, management believes the Company has sufficient liquidity to fund its operations for at least the next twelve months from the issuance date of these unaudited condensed consolidated financial statements; however, the Company may require additional capital in the future to help fund current research and development programs and operations.
Principles of Consolidation and Foreign Currency Transactions
The condensed consolidated financial statements include the accounts of International Stem Cell Corporation and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The functional currency of the Company and its wholly owned subsidiaries is the U.S. dollar. Monetary assets and liabilities that are not denominated in the functional currency are remeasured each reporting period into U.S. dollars at foreign currency exchange rates in effect at the respective balance sheet date. Non-monetary assets and liabilities and equity are remeasured at the historical exchange rates. Revenue and expenses are remeasured at the average rate in effect on the date of the transaction. Net realized and unrealized gains and losses from foreign currency transactions and remeasurement are reported in general and administrative expense in the accompanying condensed consolidated statements of operations and were not material for the periods presented.
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Significant estimates include patent life (remaining legal life versus remaining useful life), inventories carrying values, and the fair value of stock option grants using the Black-Scholes option valuation model. By their nature, estimates are subject to an inherent degree of uncertainty and actual results could differ from these estimates.
With respect to income taxes, the provision of income taxes and tax-related accounts and disclosures in the current year are subject to change. The Company has evaluated all positive and negative evidence supporting their valuation allowance and based on the supporting calculations performed both with and without the sale of LCT, the Company does not expect to realize its deferred tax assets in the foreseeable future. A full valuation allowance will continue to apply, consistent with prior periods.
Discontinued Operations
The Company presents discontinued operations when there is a disposal of a component or a group of components that represents a strategic shift that will have a major effect on operations and financial results. The results of discontinued operations are reported in net income (loss) from discontinued operations in the condensed consolidated statements of operations for all periods presented, commencing in the period in which the business is either disposed of or is classified as held for sale, including any gain or loss recognized on closing or adjustment of the carrying amount to fair value less costs to sell. Assets and liabilities related to a business classified as held for sale or that meet the criteria for discontinued operations are presented separately in the consolidated balance sheets for the current and prior periods presented. Similarly, cash flows for continuing and discontinued operations are presented separately in the consolidated statements of cash flows for the current and prior periods presented.
Prior period balances presented related to the Company’s current reportable segments and discontinued operations have been reclassified to conform to the current presentation in the consolidated financial statements. These consolidated financial statements prepared by management are unaudited and should be read in conjunction with our audited consolidated financial statements, including the accompanying notes appearing in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
Segments
The Company’s chief operating decision maker reviews financial information presented on a consolidated basis, accompanied by disaggregated information by each reportable segment's statement of operations. The Company operates the business on the basis of two reporting segments: therapeutic market (“ISCO”) and anti-aging market (“LSC”).
Inventories
Inventories are accounted for using the average cost and specific identification methods for LSC products. Inventories are stated at the lower of cost or net realizable value. Laboratory supplies used in the research and development process are expensed as consumed. As such, at each reporting period, the Company estimates its reserve allowance for excess and obsolete inventories using historical sales data and inventory turnover rates. The establishment of a reserve for excess and obsolete inventories establishes a new cost basis in inventories, and charges are not reversed subsequently to income, even if circumstances later suggest that increased carrying amounts are recoverable. If the Company is able to sell such inventories, any related reserves would be reduced in the period of sale. The value of the inventories that are not expected to be sold within one year of the current reporting period is classified as non-current inventories on the accompanying condensed consolidated balance sheets.
Accounts Receivable, net
Trade accounts receivable are recorded at the net invoice value and are not interest bearing. Accounts receivable consist of LSC trade receivable amounts related to e-tailer, spa, and distributor sales. The Company considers receivables past due based on the contractual payment terms. The Company measures expected credit losses for financial instruments at each reporting date based on historical experience, current conditions, and reasonable forecasts. The allowance for credit losses represents the Company’s estimate of expected credit losses relating to these factors. Amounts are written off against the allowance for credit losses when the Company
determines that a customer account is uncollectible. As of September 30, 2026 and December 31, 2025, the Company’s allowance for credit losses was immaterial.
Property and Equipment
Property and equipment are stated at cost. The provision for depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets, which are generally three to five years. Leasehold improvements are capitalized and amortized over the shorter of the remaining term of the lease or the estimated life of the assets.
Intangible Assets, net
Intangible assets consist of acquired patent licenses and capitalized legal fees related to the acquisition, filing, maintenance, and defense of patents and trademarks. Amortization begins once the patent is issued by the appropriate authoritative bodies. In the period in which a patent application is rejected or efforts to pursue the patent are abandoned, all the related accumulated costs are expensed. Patents and other intangible assets are amortized on a straight-line basis over the shorter of the useful life of the underlying patent, which is generally 15 years, or when the intangible asset is rejected or abandoned. All amortization expense and impairment charges related to intangible assets are recognized as general and administrative expenses in the accompanying condensed consolidated statements of operations.
Leases
The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use assets, operating lease obligations, current, and operating lease obligations, net of current portion, on the Company’s consolidated balance sheets.
Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of future minimum lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company uses a discount rate based on its estimated incremental borrowing rate to determine the right-of-use asset and operating lease liabilities to be recognized. The Company determines its incremental borrowing rate based on the terms and lease payments of its operating leases and what it would normally pay to borrow, on a collateralized basis, over similar terms for an amount equal to the lease payments. Operating lease expense is recognized on a straight-line basis over the lease term. In addition, the Company does not separate lease components from non-lease components. The Company has elected to not recognize right-of-use assets and lease liabilities for leases with an initial term of 12 months or less. The Company recognizes lease expense on a straight-line basis over the lease term beginning on the commencement date.
Long-Lived Asset Impairment
The Company reviews long-lived assets for impairment when events or changes in circumstances (“triggering event”) indicate that the carrying value of an asset or group of assets may not be recovered. If a triggering event is determined to have occurred, the carrying value of an asset or group of assets is compared to the future undiscounted cash flows expected to be generated by the asset or group of assets. If the carrying value exceeds the undiscounted cash flows of the asset or group of assets, then an impairment exists, which is measured as the excess of carrying value over the asset or asset group’s fair value. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable.
Revenue Recognition
The Company's revenue consists of sales of products from its one revenue-generating operating segment: the anti-aging market segment (LSC). The anti-aging market segment markets and sells a line of skin care products directly to customers through online orders via the ecommerce sales channel. This channel includes sales to individual consumers through the Company's website, as well as e-tailers, spas, and distributors.
The following table presents the Company's revenue (in thousands, except percentages):
LSC:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Skin care products |
|
$ |
147 |
|
|
$ |
165 |
|
|
$ |
444 |
|
|
$ |
443 |
|
Contract terms for the unit price, quantity, shipping and payment are governed by sales agreements, invoices, or online order forms, which the Company considers to be a customer's contract in all cases. The unit price is considered the observable stand-alone selling
price for the performance obligation(s) within the arrangements. Any promotional or volume sales discounts are applied evenly to the units sold for purposes of calculating standalone selling price.
The Company recognizes revenue when its customer obtains control of the promised goods or services in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. Product sales generally consist of a single performance obligation that the Company satisfies at a point in time (i.e., upon shipment of the product).
Payment terms vary by customer type. Individual customers purchasing through the Company’s website pay at the time of order, and no receivable is recorded for these sales. Certain spas, e-tailers, and distributors are granted Net 30 payment terms, measured from the date the Company satisfies its performance obligation. Accounts receivable relate exclusively to amounts due from these spas, e-tailers, and distributors.
Variable Consideration
The Company records revenue from customers in an amount that reflects the consideration it expects to be entitled to after transferring control of those goods or services to a customer. From time to time, the Company offers sales promotions on its LSC products, such as discounts and free product offers. Variable consideration is estimated at contract inception only to the extent that it is probable that a significant reversal of revenue will not occur and is updated at the end of each reporting period as additional information becomes available.
Practical Expedients
The Company has elected the practical expedient to not determine whether contracts with customers contain significant financing components. The Company pays commissions on certain sales once the customer payment has been received, which are accrued at the time of sale. The Company generally expenses sales commissions when incurred because the amortization period would be one year or less. These costs are recorded as selling and marketing expenses in the accompanying condensed consolidated statements of operations. In addition, the Company has elected to exclude sales taxes consideration from the determined transaction price.
The Company has elected to account for shipping and handling costs, recognized as cost of sales, as activities to fulfill the promise to transfer the goods to a customer. As a result, no consideration is allocated to shipping and handling costs. Rather, the Company accrues the cost of shipping and handling upon shipment of the product, and all contract revenue (i.e., the transaction price) is recognized at the same time.
Allowance for Sales Returns
The Company’s anti-aging products have a 30-day product return guarantee; however, the Company determined that there is a low probability that returns will occur based on its historical rate of returns. Historically, returns have not been significant and are recognized as a reduction to current period revenue. As of September 30, 2026 and 2025, the Company recorded no allowance for sales returns.
Cost of Sales
Cost of sales consists primarily of salaries and benefits associated with employee efforts expended directly on the production of the Company’s products as well as related direct materials, shipping costs, general laboratory supplies, and an allocation of overhead.
Research and Development Costs
Research and development costs, which are expensed as incurred, primarily consist of salaries and benefits associated with research and development personnel, overhead and occupancy costs, contract services costs, and amortization of license costs for technology used in research and development with alternative future uses, offset by the research and development tax credit provided by the Australian Taxation Office for qualified expenditures.
Australian Research and Development Tax Credit
The Company’s wholly owned subsidiary, Cyto Therapeutics, conducts various research and development activities on the Company’s product candidates in Australia. Under Australian tax law, the Australian Taxation Office provides for a refundable tax credit in the form of a cash refund equal to 43.5% of qualified research and development expenditures, not to exceed established thresholds. The Australian research and development tax incentive program is a self-assessment process, and the Australian Government has the right to review the Company’s qualifying programs and related expenditures for a period of four years. If such a review were to occur and, as a result of the review and failure of a related appeal, the qualified program and related expenditures were disqualified, the respective research and development refunds could be recalled with penalties and interest.
The refundable tax credit does not depend on the Company’s generation of future taxable income or ongoing tax status or position. Accordingly, the credit is not considered an element of income tax accounting under Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) 740 – Income Taxes. The Company uses the grant accounting model by analogy to International Accounting Standards ("IAS") 20 – Accounting for Government Grants and Disclosure of Government Assistance to account for the refundable tax credit from the Australian government. The Company recognizes the research and development tax credit as a reduction to research and development expense when there is reasonable assurance that the tax credit will be received, the relevant
expenses have been incurred, and the amount can be reliably measured. During the three and nine months ended September 30, 2026, the Company did not recognize a reduction in qualified research and development expenses. During the three and nine months ended September 30, 2025, the Company recognized a reduction in qualified research and development expenses of $0 thousand and $52 thousand, respectively.
Stock-Based Compensation
The cost of a stock-based award is measured at the grant date based on the estimated fair value of the award. Stock-based compensation is recognized as expense on a straight-line basis, net of forfeitures, which are recognized as incurred, over the requisite service period of the award. The fair value of stock options is estimated using the Black-Scholes option valuation model, which requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option.
Fair Value Measurements
The carrying amounts of the Company’s accounts receivable, accounts payable, and accrued liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. The related party note payable was repaid in full in September 2026, and no amounts were outstanding as of September 30, 2026. As of December 31, 2025, the carrying value of the Company's related party note payable did not approximate fair value. Refer to Note 7 – Related Party Transactions for further discussion.
Income Taxes
The Company uses the asset and liability method of accounting for income taxes. When the Company prepares its consolidated financial statements, it estimates income taxes based on the various jurisdictions and countries where it conducts business. This requires the Company to estimate current tax exposure and to assess temporary differences that result from differing treatments of certain items for tax and accounting purposes. Deferred income taxes are recognized based on the differences between the financial statement and income tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The Company then assesses the likelihood that deferred tax assets will be realized. Valuation allowances are established when it is more likely than not some portion or all of the deferred tax assets will not be realized. When the Company establishes a valuation allowance or increases this allowance in an accounting period, it records a corresponding tax expense in the consolidated statements of operations. The Company includes interest and penalties related to income taxes within its provision for income taxes.
Net Income (Loss) Per Share
Basic net income (loss) per share attributable to common stockholders is calculated by dividing the net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net income per share attributable to common stockholders is computed by dividing the net income attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury and two-class or “if-converted” method.
The Company’s convertible preferred stock participates in dividends with common stock and is therefore a participating security. The Company applies the two-class method when it reports net income. For the three and nine months ended September 30, 2026 and the three months ended September 30, 2025, the Company reported net income, and undistributed earnings were allocated to participating securities based on total net income. The undistributed earnings were allocated to net income from discontinued operations, net of tax and total net income, and no amount was allocated to the net loss from continuing operations, because the participating securities have no obligation to fund losses.
Potentially dilutive common stock equivalents are comprised of stock options and convertible preferred stock. Potentially dilutive securities are excluded from diluted per-share amounts when the effect is antidilutive. Because the Company reported a loss from continuing operations, which is the control number for this determination, potential common shares were antidilutive, and basic and diluted weighted-average shares outstanding were the same for continuing operations, discontinued operations, and total net income.
The following table details the composition of basic and diluted income (loss) per common share as follows ($ in thousands, except per share data):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss from continuing operations |
|
$ |
(849 |
) |
|
$ |
(691 |
) |
|
$ |
(2,465 |
) |
|
$ |
(2,383 |
) |
Net income from discontinued operations, net of tax (Note 10) |
|
|
22,627 |
|
|
|
748 |
|
|
|
23,952 |
|
|
|
2,313 |
|
Net income (loss) |
|
|
21,778 |
|
|
|
57 |
|
|
|
21,487 |
|
|
|
(70 |
) |
Less: undistributed earnings allocated to participating securities |
|
|
(10,532 |
) |
|
|
(28 |
) |
|
|
(10,403 |
) |
|
|
— |
|
Net income (loss) attributable to common stockholders, basic and diluted |
|
$ |
11,246 |
|
|
$ |
29 |
|
|
$ |
11,084 |
|
|
$ |
(70 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average number of common shares outstanding, basic and diluted |
|
|
8,028,857 |
|
|
|
8,004,389 |
|
|
|
8,012,485 |
|
|
|
8,004,389 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per common share, basic and diluted |
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations - basic and diluted |
|
$ |
(0.11 |
) |
|
$ |
(0.09 |
) |
|
$ |
(0.31 |
) |
|
$ |
(0.30 |
) |
Discontinued operations - basic and diluted |
|
$ |
1.51 |
|
|
$ |
0.09 |
|
|
$ |
1.69 |
|
|
$ |
0.29 |
|
Total net income (loss) per common share - basic and diluted |
|
$ |
1.40 |
|
|
$ |
0.00 |
|
|
$ |
1.38 |
|
|
$ |
(0.01 |
) |
For the three and nine months ended September 30, 2026 and 2025, the following common stock options and convertible preferred stock were not included in the diluted net loss per share calculation because the effect would have been anti-dilutive:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Employee stock options |
|
|
13,585,886 |
|
|
|
11,915,149 |
|
|
|
13,541,908 |
|
|
|
12,959,432 |
|
Redeemable convertible preferred stock |
|
|
2,457,143 |
|
|
|
2,457,143 |
|
|
|
2,457,143 |
|
|
|
2,457,143 |
|
Non-redeemable convertible preferred stock |
|
|
5,061,687 |
|
|
|
5,061,687 |
|
|
|
5,061,687 |
|
|
|
5,061,687 |
|
Total |
|
|
21,104,716 |
|
|
|
19,433,979 |
|
|
|
21,060,738 |
|
|
|
20,478,262 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Customer Concentrations
For the three and nine months ended September 30, 2026 and 2025, no single customer accounted for more than 10% of consolidated revenues or segment revenues for continuing operations. Additionally, no single customer accounted for more than 10% of accounts receivable, net as of September 30, 2026 and December 31, 2025 for continuing operations.
Cash Concentrations
The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.
Recently Issued Accounting Pronouncements
In November 2024, the FASB issued ASU No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40) (“ASU 2024-03”). ASU 2024-03 requires disclosure of disaggregated information about any relevant expense captions presented on the face of the consolidated statement of operations, including the following required natural expense categories: (1) purchases of inventory, (2) employee compensation, (3) depreciation, (4) intangible asset amortization, and (5) depreciation, depletion, and amortization (“DD&A”) recognized as part of oil- and gas-producing activities or other depletion expenses, as well as certain other expenses, when applicable. The new standard will be effective for annual reporting periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the potential impact that this standard may have on its consolidated financial statements and related disclosures.
2. Inventories
The components of inventories are as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
|
December 31, |
|
|
|
2026 |
|
|
2025 |
|
Raw materials |
|
$ |
178 |
|
|
$ |
157 |
|
Work in process |
|
|
49 |
|
|
|
48 |
|
Finished goods |
|
|
176 |
|
|
|
175 |
|
|
|
|
403 |
|
|
|
380 |
|
Less: allowance for inventory excess and obsolescence |
|
|
(283 |
) |
|
|
(273 |
) |
Total inventories |
|
$ |
120 |
|
|
$ |
107 |
|
|
|
|
|
|
|
|
Inventories |
|
$ |
110 |
|
|
$ |
100 |
|
Non-current inventories |
|
|
10 |
|
|
|
7 |
|
Total inventories |
|
$ |
120 |
|
|
$ |
107 |
|
3. Prepaid Expenses and Other Current Assets
The components of prepaid expenses and other current assets are as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
|
December 31, |
|
|
|
2026 |
|
|
2025 |
|
Prepaid expenses |
|
$ |
98 |
|
|
$ |
104 |
|
Australian research and development tax credit |
|
|
— |
|
|
|
52 |
|
Income taxes receivable |
|
|
8 |
|
|
|
— |
|
Other current assets |
|
|
2 |
|
|
|
10 |
|
Total prepaid expenses and other current assets |
|
$ |
108 |
|
|
$ |
166 |
|
4. Property and Equipment
Property and equipment consist of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
|
December 31, |
|
|
|
2026 |
|
|
2025 |
|
Machinery and equipment |
|
$ |
935 |
|
|
$ |
935 |
|
Computer equipment and software |
|
|
182 |
|
|
|
177 |
|
Office equipment |
|
|
42 |
|
|
|
42 |
|
Leasehold improvements |
|
|
20 |
|
|
|
14 |
|
Construction in progress |
|
|
12 |
|
|
|
12 |
|
|
|
|
1,191 |
|
|
|
1,180 |
|
Less: accumulated depreciation and amortization |
|
|
(1,172 |
) |
|
|
(1,159 |
) |
Property and equipment, net |
|
$ |
19 |
|
|
$ |
21 |
|
Depreciation and amortization expense for the three months ended September 30, 2026 and 2025 was $6 thousand and $2 thousand, respectively. Depreciation and amortization expense for the nine months ended September 30, 2026 and 2025 was $12 thousand and $4 thousand, respectively. During the three and nine months ended September 30, 2026 and 2025, the Company had immaterial transfers and disposals of fully depreciated property and equipment.
5. Intangible Assets
Intangible assets consist of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
|
December 31, |
|
|
|
2026 |
|
|
2025 |
|
Patents |
|
$ |
947 |
|
|
$ |
1,195 |
|
Less: accumulated amortization |
|
|
(525 |
) |
|
|
(627 |
) |
|
|
|
422 |
|
|
|
568 |
|
Indefinite life logos and trademarks |
|
|
62 |
|
|
|
62 |
|
Intangible assets, net |
|
$ |
484 |
|
|
$ |
630 |
|
Amortization expense for the three months ended September 30, 2026 and 2025 was $16 thousand and $19 thousand, respectively. Amortization expense for the nine months ended September 30, 2026 and 2025 was $46 thousand and $58 thousand, respectively. During the nine months ended September 30, 2026, the Company abandoned and fully impaired certain patents that the Company concluded it would no longer defend or incur additional costs to maintain. Impairment charges for the three and nine months ended September 30, 2026 was $0 and $111 thousand, respectively. There was no impairment for the three months ended September 30, 2026 or three and nine months ended September 30, 2025.
6. Convertible Preferred Stock and Stockholders’ Equity (Deficit)
Convertible Preferred Stock
As of September 30, 2026 and December 31, 2025, the Company was authorized to issue 20,000,000 shares of preferred stock, $0.001 par value per share. The Company designated 50 shares of Series D redeemable convertible preferred stock and 10,004,310 shares of Series B, Series G, and Series I-2 non-redeemable convertible preferred stock.
Non-Redeemable Convertible Preferred Stock
The Company’s Series B, Series G, and Series I-2 non-redeemable convertible preferred stock has been classified as equity on the accompanying condensed consolidated balance sheets.
The authorized, issued, and outstanding shares of non-redeemable convertible preferred stock as of September 30, 2026 consist of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares |
|
|
|
|
|
|
|
|
|
Shares |
|
|
Issued and |
|
|
Liquidation |
|
|
Carrying |
|
|
|
Authorized |
|
|
Outstanding |
|
|
Preference |
|
|
Value |
|
|
|
|
|
|
|
|
|
(in thousands) |
|
Series B |
|
|
5,000,000 |
|
|
|
250,000 |
|
|
$ |
528 |
|
|
$ |
— |
|
Series G |
|
|
5,000,000 |
|
|
|
5,000,000 |
|
|
|
5,000 |
|
|
|
5 |
|
Series I-2 |
|
|
4,310 |
|
|
|
4,310 |
|
|
|
4,310 |
|
|
|
— |
|
Total |
|
|
10,004,310 |
|
|
|
5,254,310 |
|
|
$ |
9,838 |
|
|
$ |
5 |
|
The authorized, issued and outstanding shares of non-redeemable convertible preferred stock as of December 31, 2025 consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares |
|
|
|
|
|
|
|
|
|
Shares |
|
|
Issued and |
|
|
Liquidation |
|
|
Carrying |
|
|
|
Authorized |
|
|
Outstanding |
|
|
Preference |
|
|
Value |
|
|
|
|
|
|
|
|
|
(in thousands) |
|
Series B |
|
|
5,000,000 |
|
|
|
250,000 |
|
|
$ |
516 |
|
|
$ |
— |
|
Series G |
|
|
5,000,000 |
|
|
|
5,000,000 |
|
|
|
5,000 |
|
|
|
5 |
|
Series I-2 |
|
|
4,310 |
|
|
|
4,310 |
|
|
|
4,310 |
|
|
|
— |
|
Total |
|
|
10,004,310 |
|
|
|
5,254,310 |
|
|
$ |
9,826 |
|
|
$ |
5 |
|
Series D Preferred Stock Redemption
The Company’s Series D redeemable convertible preferred stock contains a contingent redemption feature that is not solely within the Company’s control. Accordingly, the Series D redeemable convertible preferred stock is classified in temporary equity (outside of permanent equity) on the accompanying condensed consolidated balance sheets. As of September 30, 2026, management concluded the contingency is not probable of being resolved. The Company will continue to monitor the probability of the contingency event at each reporting date.
Dividends
Holders of the Company’s convertible preferred stock are entitled to participating dividends with common stock when and if declared by the Company’s Board of Directors. The Series D and G convertible preferred stock previously had rights to cumulative dividends in liquidation whether declared or not declared. Since the holders waived the rights to such dividends in 2012, this does not have an ongoing impact. No dividends have been declared during the nine months ended September 30, 2026.
Liquidation
Liquidation preference among classes of preferred shares is first with Series D with priority followed by Series G, Series B and Series I-2 on the proceeds from any sale or liquidation of the Company in an amount equal to the purchase price of shares plus (in the case of the Series B) an amount equal to 1% of the Series B original issue price for every two calendar months from February 1, 2008. Following the satisfaction of the liquidation preferences, all shares of common stock participate in any remaining distribution.
Conversion
The shares of convertible preferred stock are convertible into shares of common stock at any time, at the option of the holder. The conversion rates of the Series B, Series D, and Series I-2 are subject to anti-dilution adjustments whereby, subject to specified exceptions, if the Company issues equity securities or securities convertible into equity at a price below the applicable conversion price of the Series B, Series D, and Series I-2, the conversion price of each such series shall be adjusted downward to equal the price of the new securities. The conversion rate of the Series G is subject to a weighted-average adjustment in the event of the issuance of additional shares of common stock below the conversion price, subject to specified exceptions. The conversion price of the Series I-2 is also subject to certain resets as set forth in the Certificates of Designation, including a reverse stock split.
The following table summarizes the conversion ratio of shares of common stock into which each share of convertible preferred stock can be converted as of September 30, 2026:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion |
|
|
|
Initial |
|
|
Current |
|
|
Ratio to |
|
|
|
Conversion |
|
|
Conversion |
|
|
Common |
|
|
|
Price |
|
|
Price |
|
|
Stock |
|
Series B |
|
$ |
75.00 |
|
|
$ |
0.12 |
|
|
|
8.33 |
|
Series D |
|
$ |
37.50 |
|
|
$ |
1.75 |
|
|
|
57,142.86 |
|
Series G |
|
$ |
60.00 |
|
|
$ |
9.69 |
|
|
|
0.10 |
|
Series I-2 |
|
$ |
1.75 |
|
|
$ |
1.75 |
|
|
|
571.43 |
|
Voting
The holders of Series B, Series D, and Series G are entitled to one vote for each share of common stock into which it would convert. As long as there are at least 10 shares of Series D outstanding, the holders of Series D have (i) the right to nominate and elect two members of the Board of Directors, and (ii) the right to approve specified significant transactions affecting the Company. As long as there are at least 1,000,000 shares of Series G outstanding, the holders of Series G have the initial right to propose the nomination of two members of the Board, at least one of which such nominees shall be subject to the approval of the Company’s independent directors, for election by the stockholders at the Company’s next annual meeting of stockholders, or, elected by the full board of directors to fill a vacancy, as the case may be. At least one of the two directors nominated by holders of the Series G shall be independent. The holder of Series I-2 has no voting rights, except as required by law.
Common Stock
As of September 30, 2026 and December 31, 2025, the Company was authorized to issue 120,000,000 shares of common stock, $0.001 par value per share.
Equity Incentive Plans
The Company adopted the 2010 Equity Participation Plan, as amended (the “2010 Plan”), which provides for the grant of stock options, restricted stock, and other equity-based awards. Awards for up to 9,700,000 shares may be granted to employees, directors, and consultants under the 2010 Plan. The options granted under the 2010 Plan may be either qualified or non-qualified options. Options may be granted with different vesting terms and expire no later than 10 years from the date of grant.
In June 2020, the Company amended the 2010 Plan to extend the term of the 2010 Plan until March 2030. No other material provisions were amended.
In September 2023, the Company's Board of Directors voted to amend the 2010 Plan (“2010 Plan Amendment”) to 1) increase the number of shares that may be issued under the 2010 Plan from 9,700,000 shares to an aggregate of 30,000,000 shares of common stock and 2) increase the number of awards an employee may receive in a calendar year from 800,000 shares to 10,000,000 shares. The majority shareholders approved the 2010 Plan Amendment on September 21, 2023 and the Company filed the Notice of Internet Availability of Information Statement (the “Notice”) on September 27, 2023, noting the 2010 Plan Amendment would become effective
no earlier than 40 calendar days after the Notice was first made available to stockholders. Accordingly, on November 6, 2023, the 2010 Plan Amendment became effective.
For the three and nine months ended September 30, 2026, there were no restricted stock units granted. As of September 30, 2026, there were no restricted stock units outstanding.
Stock Options
The Company's stock option activity, involving stock options issued to employees, directors, and consultants under the 2010 Plan, for the nine months ended September 30, 2026 is summarized below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Average |
|
|
|
|
|
|
|
|
|
Weighted- |
|
|
Remaining |
|
|
Aggregate |
|
|
|
Number of |
|
|
Average |
|
|
Contractual |
|
|
Intrinsic |
|
|
|
Outstanding |
|
|
Exercise |
|
|
Term |
|
|
Value |
|
|
|
Options |
|
|
Price |
|
|
(in years) |
|
|
(in thousands) |
|
Outstanding at December 31, 2025 |
|
|
13,646,881 |
|
|
$ |
0.54 |
|
|
|
|
|
|
|
Granted |
|
|
425,168 |
|
|
$ |
0.18 |
|
|
|
|
|
|
|
Exercised |
|
|
(159,000 |
) |
|
$ |
0.14 |
|
|
|
|
|
|
|
Expired |
|
|
(460,500 |
) |
|
$ |
2.93 |
|
|
|
|
|
|
|
Outstanding at September 30, 2026 |
|
|
13,452,549 |
|
|
$ |
0.45 |
|
|
|
5.80 |
|
|
$ |
1,272 |
|
Vested and expected to vest at September 30, 2026 |
|
|
13,440,838 |
|
|
$ |
0.45 |
|
|
|
5.80 |
|
|
$ |
1,270 |
|
Exercisable at September 30, 2026 |
|
|
12,979,784 |
|
|
$ |
0.46 |
|
|
|
5.69 |
|
|
$ |
1,201 |
|
The fair value of stock options granted is estimated at the date of grant using the Black-Scholes option valuation model. The weighted-average assumptions used in the Black-Scholes option valuation model to determine the fair value of stock options granted for the nine months ended September 30, 2026 and 2025 is summarized in the table below. There were no stock options granted during the three months ended September 30, 2026 and 2025.
|
|
|
|
|
Nine Months Ended September 30, |
|
2026 |
|
2025 |
Risk-free interest rate |
4.16% |
|
3.98% |
Expected stock price volatility |
118.79% |
|
126.78% |
Expected dividend yield |
0% |
|
0% |
Expected life of options (in years) |
5.34 |
|
5.32 |
Weighted-average grant date fair value |
0.14 |
|
$0.11 |
Total stock-based compensation expense recorded in the condensed consolidated statements of operations, including amounts attributable to discontinued operations, is as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
General and administrative |
|
$ |
29 |
|
|
$ |
52 |
|
|
$ |
131 |
|
|
$ |
172 |
|
Research and development |
|
|
6 |
|
|
|
11 |
|
|
|
27 |
|
|
|
52 |
|
Total |
|
$ |
35 |
|
|
$ |
63 |
|
|
$ |
158 |
|
|
$ |
224 |
|
Total stock-based compensation expense from discontinued operations for the three and nine months ended September 30, 2026 was $2 thousand and $20 thousand, respectively. Total stock-based compensation expense from discontinued operations for the three and nine months ended September 30, 2025 was $9 thousand and $36 thousand, respectively.
Unrecognized compensation expense related to stock options as of September 30, 2026 was $48 thousand, which is expected to be recognized over a weighted-average period of 0.60 years.
Common Stock Reserved for Future Issuance
As of September 30, 2026, the Company had shares of common stock reserved for future issuance as follows:
|
|
|
|
|
Options outstanding |
|
|
13,452,549 |
|
Common stock available for issuance under the 2010 Plan |
|
|
16,379,775 |
|
Redeemable convertible preferred stock |
|
|
2,457,143 |
|
Non-redeemable convertible preferred stock |
|
|
5,061,687 |
|
Total |
|
|
37,351,154 |
|
7. Related Party Transactions
Related party lease arrangements
On October 26, 2021, the Company and S Real Estate Holdings LLC jointly entered into a lease agreement with Rehco Holdings, LLC (the “Lease”), for the purpose of establishing a new corporate headquarters, including corporate, R&D, and manufacturing operations. The Lease was personally guaranteed by Dr. Russell Kern, the Company’s Executive Vice President and Chief Scientific Officer.
On December 15, 2021, the Company and S Real Estate Holdings LLC entered into a co-tenant agreement, whereby the Company and S Real Estate Holdings LLC agreed to allocate portions of the base rent and variable charges, including insurance, maintenance costs, taxes, and operating expenses, between the parties. During the term of the Lease, the Company was liable for 40% of all costs incurred in connection with the Lease. In February 2025, the Company amended its co-tenant agreement to re-allocate portions of the base rent and variable charges. Retroactively, as of January 2025, the Company became liable for 75% of all costs incurred in connection with the lease.
Refer to Note 8 – Commitments and Contingencies for further discussion.
Related party note payable
Between March 2018 and September 2022, to obtain funding for working capital purposes, the Company borrowed a total of $2.9 million from Dr. Semechkin, Co-Chairman and CEO, and issued an unsecured, non-convertible promissory note in the principal amount of $2.9 million (the “Note”) to Dr. Semechkin (the "Noteholder"). The outstanding principal amount under the Note accrued interest at a rate of 4.5% per annum. The outstanding principal and accrued interest on the Note were due and payable on March 15, 2023 and could be pre-paid without penalty at any time. There were no debt issuance fees associated with this issuance.
During 2023, the Note was amended several times, with the final amendment resulting in the issuance of the new promissory note in September 2023 ("September 2023 Note") with a maturity date of September 15, 2024. The September 2023 Note had a principal balance of $2.9 million, an interest rate of 4.5%, optional prepayment terms, and no associated debt issuance fees. All amendments during the year ended December 31, 2023 qualified as troubled debt restructurings, which did not result in a gain as the carrying amount of the debt was less than the total future cash payments of the restructured debt.
In September 2024, the Company surrendered its September 2023 Note and entered into a new agreement ("September 2024 Note"), which included repaying $0.2 million in outstanding principal, reducing the principal balance to $2.7 million, increasing the interest rate from 4.5% to 5.5%, and extending the maturity date from September 15, 2024 to September 15, 2025. All other terms of the September 2024 Note are the same as the previously outstanding note and there were no debt issuance fees associated with this issuance. Pursuant to ASC 470-60, the amendment did not qualify as a troubled debt restructuring as the creditor did not grant a concession. As the terms of the September 2024 Note were not substantially different than the terms of the September 2023 Note, the amendment was accounted for as a debt modification. The repayment of principal was accounted for as a partial extinguishment of debt, which did not result in an extinguishment gain or loss.
In June 2025, the Company repaid $0.2 million in outstanding principal, reducing the principal balance to $2.5 million. In September 2025, the Company surrendered its September 2024 Note and entered into a new agreement ("September 2025 Note"), which included extending the maturity date from September 15, 2025 to September 15, 2026. All other terms of the September 2025 Note are the same as the previously outstanding note and there were no debt issuance fees associated with this issuance. Pursuant to ASC 470-60, the amendment did not qualify as a troubled debt restructuring as the creditor did not grant a concession. As the terms of the September 2025 Note were not substantially different than the terms of the September 2024 Note, the amendment was accounted for as a debt modification. In February 2026, the Company repaid an additional $0.15 million in outstanding principal on the September 2025 Note, reducing the principal balance to $2.35 million. The repayment of principal was accounted for as a partial extinguishment of debt, which did not result in an extinguishment gain or loss.
In September 2026, the Company repaid the remaining outstanding principal of $2.35 million and accrued interest of $0.9 million on the September 2025 Note, upon maturity. The repayment and settlement of the September 2025 Note did not result in a gain or loss on extinguishment. As of September 30, 2026, no amounts were outstanding under the related party note payable.
8. Commitments and Contingencies
Leases
The Company has two operating leases for real estate in California:
•San Diego Headquarters Lease (San Diego, California) – corporate headquarters, including corporate, R&D, and manufacturing operations, with a termination date of December 2026, jointly leased with a related party (refer to Note 7 – Related Party Transactions for further discussion). This lease contains no renewal or term extension options; and
•San Diego Supplemental Office Lease (San Diego, California) – supplemental office space adjacent to the Company’s corporate headquarters with a termination date of December 2026. This lease contains no renewal or term extension options.
In October 2021, the Company entered into an operating lease for its new corporate headquarters. The lease commenced in November 2021 and expires on December 31, 2026. At commencement, base rent due under the lease was approximately $11 thousand and increases approximately 3.5% per annum over the lease term. The lease is subject to additional variable charges, including insurance, maintenance costs, taxes, and operating expenses. Base rent and additional variable charges are shared between the Company and S Real Estate Holdings LLC, a related party, with base rent for months two through five of the lease term abated by 50%.
In November 2021, the Company entered into an operating lease for supplemental office space adjacent to its new corporate headquarters with the same landlord. The lease commenced in December 2021 and expires on December 31, 2026 and is not subject to the co-tenant agreement with S Real Estate Holdings LLC. At commencement, base rent due under the supplemental office lease was approximately $4 thousand per month and increases at a fixed amount per annum over the lease term. At lease commencement, the Company recognized a right-of-use asset and lease liabilities of approximately $247 thousand. In January 2025, the Company agreed to an addition on the San Diego Supplemental Office Lease. Base rent due under the new lease addition was approximately $4 thousand per month. At lease commencement, the Company recognized a right-of-use asset and lease liabilities of approximately $93 thousand.
In February 2025, the Company and S Real Estate Holdings, LLC, a related party, amended its co-tenant agreement to re-allocate portions of the base rent and variable charges. Retroactively, as of January 2025, the Company became liable for 75% of all costs incurred in connection with the lease. As a result of the amended co-tenant agreement, the Company recognized a lease liability and right-of-use asset as of the modification date.
The Company’s operating leases for real estate are subject to additional variable charges for common area maintenance and other variable costs. Variable costs for the three and nine months ended September 30, 2026 and 2025 were immaterial. All operating lease expense is recognized on a straight-line basis over the lease term. For the three months ended September 30, 2026 and 2025, lease expense totaled $41 thousand and $41 thousand, respectively. For the nine months ended September 30, 2026 and 2025, lease expense totaled $124 thousand and $124 thousand, respectively. As of September 30, 2026 and December 31, 2025, the Company had no finance leases.
Maturities of lease liabilities are as follows (in thousands):
|
|
|
|
|
Years ending December 31, |
|
|
|
2026 (remaining three months) |
|
$ |
(39 |
) |
Total minimum lease payments |
|
|
(39 |
) |
Less: imputed interest |
|
|
— |
|
Total future minimum lease payments |
|
|
(39 |
) |
Less: operating lease liabilities, current |
|
|
39 |
|
Operating lease liabilities, net of current portion |
|
$ |
— |
|
9. Segments
The Company operates the business on the basis of two reporting segments: therapeutic market (“ISCO”) and anti-aging market (“LSC”).
The Company does not measure the performance of its segments on any asset-based metrics. Therefore, segment information is presented only for the results of operations. Results of operations for the three and nine months ended September 30, 2026 and 2025 by reporting segment were as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, 2026 |
|
|
|
ISCO |
|
|
LSC |
|
|
Total |
|
Product sales |
|
$ |
— |
|
|
$ |
147 |
|
|
$ |
147 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
Cost of sales |
|
|
— |
|
|
|
71 |
|
|
|
71 |
|
General and administrative |
|
|
580 |
|
|
|
127 |
|
|
|
707 |
|
Selling and marketing |
|
|
— |
|
|
|
84 |
|
|
|
84 |
|
Research and development |
|
|
98 |
|
|
|
8 |
|
|
|
106 |
|
Total operating expenses |
|
|
678 |
|
|
|
290 |
|
|
|
968 |
|
Loss from operations |
|
$ |
(678 |
) |
|
$ |
(143 |
) |
|
$ |
(821 |
) |
Total other expense, net |
|
|
|
|
|
|
|
|
(28 |
) |
Net loss from continuing operations |
|
|
|
|
|
|
|
$ |
(849 |
) |
|
|
|
|
|
|
|
|
|
|
Additional Segment Information |
|
|
|
|
|
|
|
|
|
Interest expense (1) |
|
$ |
(29 |
) |
|
$ |
— |
|
|
$ |
(29 |
) |
Depreciation and amortization |
|
$ |
21 |
|
|
$ |
1 |
|
|
$ |
22 |
|
Share-based compensation expense |
|
$ |
29 |
|
|
$ |
4 |
|
|
$ |
33 |
|
|
|
|
|
|
|
|
|
|
|
(1) Includes interest expense and interest expense - related party. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, 2025 |
|
|
|
ISCO |
|
|
LSC |
|
|
Total |
|
Product sales |
|
$ |
— |
|
|
$ |
165 |
|
|
$ |
165 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
Cost of sales |
|
|
— |
|
|
|
37 |
|
|
|
37 |
|
General and administrative |
|
|
494 |
|
|
|
108 |
|
|
|
602 |
|
Selling and marketing |
|
|
— |
|
|
|
100 |
|
|
|
100 |
|
Research and development |
|
|
72 |
|
|
|
8 |
|
|
|
80 |
|
Total operating expenses |
|
|
566 |
|
|
|
253 |
|
|
|
819 |
|
Loss from operations |
|
$ |
(566 |
) |
|
$ |
(88 |
) |
|
$ |
(654 |
) |
Total other expense, net |
|
|
|
|
|
|
|
|
(37 |
) |
Net loss from continuing operations |
|
|
|
|
|
|
|
$ |
(691 |
) |
|
|
|
|
|
|
|
|
|
|
Additional Segment Information |
|
|
|
|
|
|
|
|
|
Interest expense (1) |
|
$ |
(37 |
) |
|
$ |
— |
|
|
$ |
(37 |
) |
Depreciation and amortization |
|
$ |
21 |
|
|
$ |
1 |
|
|
$ |
22 |
|
Share-based compensation expense |
|
$ |
48 |
|
|
$ |
6 |
|
|
$ |
54 |
|
|
|
|
|
|
|
|
|
|
|
(1) Includes interest expense and interest expense - related party. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30, 2026 |
|
|
|
ISCO |
|
|
LSC |
|
|
Total |
|
Product sales |
|
$ |
— |
|
|
$ |
444 |
|
|
$ |
444 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
Cost of sales |
|
|
— |
|
|
|
142 |
|
|
|
142 |
|
General and administrative |
|
|
1,785 |
|
|
|
347 |
|
|
|
2,132 |
|
Selling and marketing |
|
|
— |
|
|
|
271 |
|
|
|
271 |
|
Research and development |
|
|
250 |
|
|
|
20 |
|
|
|
270 |
|
Total operating expenses |
|
|
2,035 |
|
|
|
780 |
|
|
|
2,815 |
|
Loss from operations |
|
$ |
(2,035 |
) |
|
$ |
(336 |
) |
|
$ |
(2,371 |
) |
Total other expense, net |
|
|
|
|
|
|
|
|
(94 |
) |
Net loss from continuing operations |
|
|
|
|
|
|
|
$ |
(2,465 |
) |
|
|
|
|
|
|
|
|
|
|
Additional Segment Information |
|
|
|
|
|
|
|
|
|
Interest expense (1) |
|
$ |
(98 |
) |
|
$ |
— |
|
|
$ |
(98 |
) |
Depreciation and amortization |
|
$ |
56 |
|
|
$ |
2 |
|
|
$ |
58 |
|
Share-based compensation expense |
|
$ |
123 |
|
|
$ |
15 |
|
|
$ |
138 |
|
|
|
|
|
|
|
|
|
|
|
(1) Includes interest expense and interest expense - related party. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30, 2025 |
|
|
|
ISCO |
|
|
LSC |
|
|
Total |
|
Product sales |
|
$ |
— |
|
|
$ |
443 |
|
|
$ |
443 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
Cost of sales |
|
|
— |
|
|
|
147 |
|
|
|
147 |
|
General and administrative |
|
|
1,615 |
|
|
|
359 |
|
|
|
1,974 |
|
Selling and marketing |
|
|
— |
|
|
|
295 |
|
|
|
295 |
|
Research and development |
|
|
267 |
|
|
|
27 |
|
|
|
294 |
|
Total operating expenses |
|
|
1,882 |
|
|
|
828 |
|
|
|
2,710 |
|
Loss from operations |
|
$ |
(1,882 |
) |
|
$ |
(385 |
) |
|
$ |
(2,267 |
) |
Total other expense, net |
|
|
|
|
|
|
|
|
(116 |
) |
Net loss from continuing operations |
|
|
|
|
|
|
|
$ |
(2,383 |
) |
|
|
|
|
|
|
|
|
|
|
Additional Segment Information |
|
|
|
|
|
|
|
|
|
Interest expense (1) |
|
$ |
(116 |
) |
|
$ |
— |
|
|
$ |
(116 |
) |
Depreciation and amortization |
|
$ |
60 |
|
|
$ |
2 |
|
|
$ |
62 |
|
Share-based compensation expense |
|
$ |
150 |
|
|
$ |
38 |
|
|
$ |
188 |
|
|
|
|
|
|
|
|
|
|
|
(1) Includes interest expense and interest expense - related party. |
|
|
|
|
|
|
|
|
|
10. Discontinued Operations
On July 10, 2026, the Company entered into a definitive Membership Interest Purchase Agreement (the "MIPA") with American Type Culture Collection, Inc. ("ATCC"), pursuant to which the Company agreed to sell 100% of the membership interests of Lifeline Cell Technology, LLC ("LCT"), its subsidiary engaged in the development, manufacture, and sale of biological materials and reagents for scientific research, to ATCC (the "Transaction"). On September 1, 2026, the Company completed the sale.
At closing, the Company received net cash consideration of $23.1 million, recognized $2.6 million of escrow receivable, slightly offset by a known adjustment to working capital, for total net consideration of $25.6 million. The escrow receivable is reported separately on the consolidated balance sheet. The total consideration is subject to customary post-closing adjustments for working capital.
Net cash proceeds presented in investing activities of $21.7 million consist primarily of cash received at closing of $23.1 million, less cash divested with LCT of $19 thousand, and transaction costs paid of approximately $1.2 million. The $2.6 million escrow
receivable and the $40 thousand payable to ATCC for the working capital true-up are non-cash and are presented in the supplemental disclosure of non-cash investing activities in the condensed consolidated statements of cash flows.
The $2.6 million escrow consists of a $2.5 million indemnity escrow and a $0.1 million adjustment escrow. The adjustment escrow secures any amount owed to ATCC from the post-closing working capital true-up. The indemnity escrow secures the Company's indemnification obligations to ATCC under the MIPA. Six months after the closing date, $1.5 million of the indemnity escrow will be released to the Company, net of amounts needed for any pending claims, and the remaining balance will be released nine months after the closing date, net of any pending claims. General representations and warranties survive for nine months, subject to a $25 thousand deductible, and the indemnity escrow is the sole source of recovery for claims for breaches of general representations, except for fraud, tax matters and certain fundamental and specified representations.
The Company recognized a pre-tax gain of $21.8 million on the sale, calculated as the difference between the consideration received for the sale of LCT less costs to sell and the carrying value of the net assets of LCT. As a result of this gain, the Company recognized $0.2 million of income tax expense. The gain and income tax expense are reflected in net income from discontinued operations, net of tax.
Income tax expense of $0.2 million for the three- and nine-month periods ended September 30, 2026, was primarily attributable to the taxable gain from discontinued operations, partially offset by the utilization of historical net operating loss ("NOL") carryforwards and research and development ("R&D") tax credits. The Company previously completed analyses under Internal Revenue Code Section 382, which identified limitations on the utilization of its net operating loss ("NOL") carryforwards. As a result of these limitations and the applicable statutory carryforward periods, approximately $52 million of NOLs are expected to expire unused. $14.7 million of the remaining NOLs of $20.7 million were used to offset the calculated taxable gain on the discontinued operations under the intraperiod allocation guidance in ASC 740-20-45. Similarly, the Company had Federal and California R&D tax credit carryovers from prior periods. These R&D tax credit carryforwards were ultimately used to offset a portion of the Federal and California tax generated on the discontinued operations. As discussed in Use of Estimates section of Note 1, these totals are subject to change as a complete R&D analysis is finalized. The Company has evaluated all positive and negative evidence supporting their valuation allowance and based on the supporting calculations performed both with and without the sale of LCT, the Company does not expect to realize its deferred tax assets in the foreseeable future. A full valuation allowance will continue to apply.
Also in connection with the sale, the Company and ATCC entered into a transition services agreement (TSA) for a period of six months following the closing of the Transaction. Under the TSA, the Company provides ATCC with various transition services, including IP and contract services, accounting support, IT support, data migration, human resources, and product related services, and similarly, ATCC will provide the Company various services including audit close and process support. There were no earnings related to the TSA for the three and nine months ended September 30, 2026. The Company does not expect the TSA to result in significant continuing involvement in the operations of LCT.
The results of the LCT business (previously reported as a separate reporting segment), as well as the associated gain, have been reflected as discontinued operations in the Company’s consolidated statements of earnings as net income from discontinued operations, net of taxes. The assets and liabilities associated with the LCT business were classified as assets and liabilities of discontinued operations in the consolidated balance sheets. Prior periods have been recast to reflect this presentation.
Details of net income from discontinued operations related to LCT are as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Product sales |
|
$ |
1,811 |
|
|
$ |
2,204 |
|
|
$ |
6,505 |
|
|
$ |
6,502 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales |
|
|
868 |
|
|
|
1,011 |
|
|
|
2,968 |
|
|
|
2,820 |
|
General and administrative |
|
|
(241 |
) |
|
|
187 |
|
|
|
519 |
|
|
|
612 |
|
Selling and marketing |
|
|
124 |
|
|
|
180 |
|
|
|
486 |
|
|
|
544 |
|
Research and development |
|
|
42 |
|
|
|
78 |
|
|
|
189 |
|
|
|
213 |
|
Total operating expenses |
|
|
793 |
|
|
|
1,456 |
|
|
|
4,162 |
|
|
|
4,189 |
|
Operating income from discontinued operations |
|
|
1,018 |
|
|
|
748 |
|
|
|
2,343 |
|
|
|
2,313 |
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
Other expense |
|
|
(2 |
) |
|
|
— |
|
|
|
(2 |
) |
|
|
— |
|
Total other expense, net |
|
|
(2 |
) |
|
|
— |
|
|
|
(2 |
) |
|
|
— |
|
Income from discontinued operations, before gain on sale and provision for taxes |
|
|
1,016 |
|
|
|
748 |
|
|
|
2,341 |
|
|
|
2,313 |
|
Gain on sale of business |
|
|
21,765 |
|
|
|
— |
|
|
|
21,765 |
|
|
|
— |
|
Income from discontinued operations, before provision for taxes |
|
|
22,781 |
|
|
|
748 |
|
|
|
24,106 |
|
|
|
2,313 |
|
Provision for taxes from discontinued operations |
|
|
154 |
|
|
|
— |
|
|
|
154 |
|
|
|
— |
|
Net income from discontinued operations, net of tax |
|
|
22,627 |
|
|
|
748 |
|
|
|
23,952 |
|
|
|
2,313 |
|
General and administrative expenses of discontinued operations is a net credit of $241 thousand for the three months ended September 30, 2026. The net credit is primarily driven by the reclassification of transaction costs for legal fees from general and administrative expenses to costs to sell. Those costs reduce the gain on disposal and are presented in the gain on sale of business line item.
Details of assets and liabilities of discontinued operations related to LCT are as follows (in thousands):
|
|
|
|
|
|
|
December 31, |
|
|
|
2025 |
|
Assets |
|
|
|
Current assets: |
|
|
|
Cash |
|
$ |
200 |
|
Accounts receivable, net |
|
|
718 |
|
Inventories |
|
|
1,414 |
|
Prepaid expenses and other current assets |
|
|
15 |
|
Total current assets of discontinued operations |
|
|
2,347 |
|
Non-current inventories |
|
|
222 |
|
Property and equipment, net |
|
|
139 |
|
Intangible assets, net |
|
|
14 |
|
Right-of-use assets |
|
|
190 |
|
Deposits and other assets |
|
|
17 |
|
Total assets of discontinued operations |
|
$ |
2,929 |
|
Liabilities |
|
|
|
Current liabilities: |
|
|
|
Accounts payable |
|
$ |
59 |
|
Accrued liabilities |
|
|
123 |
|
Operating lease liabilities, current |
|
|
227 |
|
Total current liabilities of discontinued operations |
|
|
409 |
|
Operating lease liabilities, net of current portion |
|
|
— |
|
Total liabilities of discontinued operations |
|
$ |
409 |
|
The assets and liabilities of discontinued operations at December 31, 2025 include a right-of-use asset of $190 thousand and operating lease liabilities of $227 thousand for LCT's facility lease in Maryland, for which LCT was the lessee. The lease transferred to ATCC with LCT at the time of closing.
11. Subsequent Events
On October 19, 2026, the Board approved a one-time discretionary cash bonus to executives totaling $2.4 million that was paid on October 20, 2026.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes and other financial information included elsewhere herein. This information should also be read in conjunction with our audited historical consolidated financial statements which are included in our Form 10-K for the fiscal year ended December 31, 2025 (“Form 10-K”). The discussion contains forward-looking statements, such as our plans, expectations and intentions (including those related to clinical trials and business and expense trends), that are based upon current expectations and that involve risks and uncertainties. Our actual results may differ significantly from management’s expectations. The factors that could affect these forward-looking statements are discussed in the Risk Factors included in our Form 10-K and in Part II, Item 1A of this Quarterly Report on Form 10-Q. This discussion should not be construed to imply that the results discussed herein will necessarily continue into the future, or that any expectations expressed herein will necessarily be indicative of actual operating results in the future. Such discussion represents only the best assessment by our management.
Business Overview
We are a California-based clinical stage biotechnology company developing stem cell-based therapies and anti-aging products. We were the first company to take a pluripotent stem cell-derived therapy for Parkinson's disease into clinical trials. We have generated aggregate anti-aging product revenues from our one commercial business of $0.1 million and $0.2 million for the three months ended September 30, 2026 and 2025, respectively, and $0.4 million and $0.4 million for the nine months ended September 30, 2026 and 2025, respectively. We currently have no revenue generated from our principal operations in therapeutic product development.
Our platform is based on a proprietary class of pluripotent stem cells: human parthenogenetic stem cells (“hpSCs”). We believe hpSCs offer three key advantages:
Versatility: hpSCs have the potential to differentiate into many different cell types in the human body, supporting multiple potential products from a single platform.
No embryo destruction: The derivation of hpSCs does not require the destruction of viable human embryos.
Immune matching: hpSCs offer the potential to create immune-matched cells and tissues that are less likely to be rejected after transplantation. Our UniStemCell collection currently includes 15 hpSC lines. We have manufacturing protocols that comply with Good Manufacturing Practice (“GMP”) standards under the U.S. Code of Federal Regulations, as enforced by the United States Food and Drug Administration (“FDA”).
Recent Developments
Sale of Lifeline Cell Technology, LLC ("LCT")
On July 10, 2026, we entered into a Membership Interest Purchase Agreement (the "MIPA") with American Type Culture Collection, Inc. ("ATCC"), pursuant to which we agreed to sell 100% of the membership interests of Lifeline Cell Technology, LLC ("LCT"), our subsidiary engaged in the development, manufacture, and sale of biological materials and reagents for scientific research, to ATCC (the "Transaction"). The Transaction closed on September 1, 2026.
At closing, we received net cash consideration of $23.1 million, recognized $2.6 million of escrow receivable, slightly offset by a known adjustment to working capital, for total net consideration of $25.6 million. The escrow receivable is reported separately on the consolidated balance sheet. The total consideration is subject to customary post-closing adjustments for working capital.
Following the completion of the sale, we now operate our business on the basis of two reporting segments: therapeutic market (“ISCO”) and anti-aging market (“LSC”).
Unless otherwise indicated, the information in the remaining discussion refers only to our continuing operations.
Market Opportunity and Growth Strategy
Therapeutic Market – Clinical Applications of hpSCs for Disease Treatments
We were the first company to take a pluripotent stem cell-derived therapy for PD into clinical trials. Our proprietary, clinical-grade neural stem cell therapy, ISC-hpNSC®, is derived from human parthenogenetic stem cells, a source that does not require destroying a human embryo. We are developing it for PD, stroke, and traumatic brain injury (TBI).
We target conditions where the rationale for cell therapy is strong and the supply of functional cells is the limiting factor. Because one product serves all three indications, we believe data generated in PD can reduce the risk and cost of our stroke and TBI programs.
PD: Our most advanced project is the neural stem cell program for the treatment of Parkinson’s disease. In 2013, we published in Nature Scientific Reports the basis for our patent on a new method of manufacturing neural stem cells, which is used to produce the clinical-grade cells necessary for future clinical studies and commercialization. In 2014, we completed the majority of the preclinical research, establishing the safety profile of NSC in various animal species, including non-human primates. In June 2016, we published
the results of a 12-month preclinical non-human primate study, which demonstrated the safety, efficacy, and mechanism of action of the ISC- hpNSC®. In 2017, we dosed four patients in our Phase I trial of ISC-hpNSC®, human parthenogenetic stem cell-derived neural stem cells for the treatment of Parkinson’s disease. We reported 12-month results from the first cohort and 6-month interim results of the second cohort at the Society for Neuroscience annual meeting (Neuroscience 2018) in November 2018. In April 2019, we announced the completion of subject enrollment, with the 12th subject receiving a transplantation of the highest dose of cells. There have been no safety signals or serious adverse effects seen to date as related to the transplanted ISC-hpNSC® cells.
We announced the successful completion of the dose escalating phase 1 clinical trial in June 2021. In terms of preliminary efficacy, where scores are compared against baseline before transplantation, we observed a potential dose-dependent response with an apparent peak effectiveness at our middle dose. The % OFF-Time, which is the time during the day when levodopa medication is not performing optimally and PD symptoms return, decreased an average 47% from the baseline at 12 months post transplantation in cohort 2. This trend continued through 24 months where the % OFF-Time in the second cohort dropped by 55% from the initial reading. The same was true for % ON-Time without dyskinesia, which is the time during the day when levodopa medication is performing optimally without dyskinesia. The % ON-Time increased an average of 42% above the initial evaluation at 12 months post-transplantation in the second cohort.
Stroke: In August 2014, we announced the launch of a stroke program, evaluating the use of ISC-hpNSC® transplantation for the treatment of ischemic stroke using a rodent model of the disease. The Company has a considerable amount of safety data on ISC-hpNSC® from the Parkinson’s disease program and, as there is evidence that transplantation of ISC-hpNSC® may improve patient outcomes as an adjunctive therapeutic strategy in stroke, having a second program that can use this safety dataset is therefore a logical extension. In 2015, the Company together with Tulane University demonstrated that NSC can significantly reduce neurological dysfunction after a stroke in animal models.
TBI: In October 2016, we announced the results of the preclinical rodent study, evaluating the use of ISC-hpNSC® transplantation for the treatment of TBI. The study was conducted at the University of South Florida Morsani College of Medicine. We demonstrated that animals receiving injections of ISC-hpNSC® displayed the highest levels of improvements in cognitive performance and motor coordination compared to vehicle control treated animals. In February 2019, we published the results of the preclinical study in Theranostics, a prestigious peer-reviewed medical journal. The publication titled, “Human parthenogenetic neural stem cell grafts promote multiple regenerative processes in a traumatic brain injury model,” demonstrated that the clinical-grade neural stem cells used in our Parkinson’s disease clinical trial, ISC-hpNSC®, significantly improved TBI-associated motor, neurological, and cognitive deficits without any safety issues.
Anti-Aging Cosmetic Market – Skin Care Products
Our wholly owned subsidiary Lifeline Skin Care, Inc. (“LSC”) develops, manufactures, and sells skin care products based on two core technologies: encapsulated peptides derived from hpSC and specially discovered small molecules. LSC’s products include:
•Lifeline ProPlus Advanced Defense Complex
•Lifeline ProPlus Advanced Recovery Complex
•Lifeline ProPlus Eye Firming Complex
•Lifeline ProPlus Neck Firming Complex
•Lifeline ProPlus Advanced Aquoues Treatment
•Lifeline ProPlus Collagen Booster (Advanced Molecular Serum)
•Lifeline ProPlus Elastin Booster
•Lifeline ProPlus Brightening Toner
LSC’s products are regulated as cosmetics. LSC’s products are sold domestically through a branded website and directly to e-tailers, spas, and distributors under a single ecommerce sales channel.
Results of Operations
Comparison of the Three Months Ended September 30, 2026 and 2025
The following table summarizes our results of operations for the three months ended September 30, 2026 and 2025 (in thousands, except percentages):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
|
2026 |
|
|
2025 |
|
|
$ Change |
|
|
% Change |
|
Product sales |
|
$ |
147 |
|
|
$ |
165 |
|
|
$ |
(18 |
) |
|
|
-11 |
% |
Cost of sales |
|
|
71 |
|
|
|
37 |
|
|
|
34 |
|
|
|
92 |
% |
Profit margin |
|
|
76 |
|
|
|
128 |
|
|
|
(52 |
) |
|
|
-41 |
% |
As a % of revenues |
|
|
52 |
% |
|
|
78 |
% |
|
|
|
|
|
|
General and administrative |
|
|
707 |
|
|
|
602 |
|
|
|
105 |
|
|
|
17 |
% |
Selling and marketing |
|
|
84 |
|
|
|
100 |
|
|
|
(16 |
) |
|
|
-16 |
% |
Research and development |
|
|
106 |
|
|
|
80 |
|
|
|
26 |
|
|
|
33 |
% |
Other expense |
|
|
(28 |
) |
|
|
(37 |
) |
|
|
9 |
|
|
|
-24 |
% |
Net loss from continuing operations |
|
|
(849 |
) |
|
|
(691 |
) |
|
|
(158 |
) |
|
|
23 |
% |
Net income from discontinued operations, net of tax |
|
|
22,627 |
|
|
|
748 |
|
|
|
21,879 |
|
|
|
|
Net income |
|
$ |
21,778 |
|
|
$ |
57 |
|
|
$ |
21,721 |
|
|
|
38107 |
% |
As a % of revenues |
|
|
14815 |
% |
|
|
35 |
% |
|
|
|
|
|
|
Product sales, net
Product sales for the three months ended September 30, 2026 were $147 thousand compared to $165 thousand for the three months ended September 30, 2025. This decrease of $18 thousand, or 11%, was driven by a decrease in product sales from our skin care product line due to lower repeat purchasing across direct-to-consumer, wholesale, and reseller channels.
Cost of sales
Cost of sales for the three months ended September 30, 2026 were $71 thousand, compared to $37 thousand for the three months ended September 30, 2025. The increase of $34 thousand, or 92%, was driven primarily by a $34 thousand increase in the inventory reserve adjustment moving from a negative $13 thousand in 2025 as a result of sales of previously reserved finished goods, to a $21 thousand dollar reserve increase in the current quarter as a result of slower moving inventory due to decreased sales. There was also an increase in shipping costs, and these increases were slightly offset by decreased cost of goods sold, driven by decreased product sales.
Profit margins as a percentage of revenue have decreased approximately 26% for the three months ended September 30, 2026, as compared to the three months ended September 30, 2025. The net decrease in gross margins was driven by the factors discussed above, including the change in the inventory reserve adjustment between the current and prior year period.
Cost of sales consists primarily of salaries and benefits associated with employee efforts expended directly on the production of the Company’s products, as well as related direct materials, general laboratory supplies, and the allocation of overhead. We plan to continue to refine our manufacturing processes and supply chain management to improve the cost of sales as a percentage of revenue for our LSC segment.
General and administrative expenses
General and administrative expenses for the three months ended September 30, 2026 were $707 thousand, compared to $602 thousand for the three months ended September 30, 2025. The increase of $105 thousand, or 17%, was primarily attributable to an increase of $108 thousand in audit fees and $54 thousand in personnel related costs and $5 thousand related to general liability insurance fees. These increases were partially offset by $51 thousand decrease in consulting fees combined with a $15 thousand decrease in D&O insurance expenses.
Our general and administrative expenses consist primarily of employee-related expenses including salaries, bonuses, benefits, and stock-based compensation. Other significant costs include facility costs not otherwise included in or allocated to other departments, legal fees not relating to patents and corporate matters, and fees for accounting and consulting services.
Selling and marketing expenses
Selling and marketing expenses for the three months ended September 30, 2026 were $84 thousand, compared to $100 thousand for the three months ended September 30, 2025. The decrease of $16 thousand, or 16%, was primarily attributable to a decrease of approximately $13 thousand in personnel related costs combined with $5 thousand in web site and SEM related advertising partially offset by an increase of $2 thousand in dues and subscription costs.
Our selling and marketing expenses consist primarily of employee-related expenses including salaries, bonuses, benefits, and stock-based compensation for our anti-aging cosmetic business. Other significant costs include facility costs not otherwise included in or allocated to other departments, as well as marketing material costs, permits and licenses for ecommerce, and other advertising expenses.
Research and development expenses
Research and development expenses for the three months ended September 30, 2026 were $106 thousand, compared to $80 thousand for the three months ended September 30, 2025. The increase of $26 thousand, or 33%, was primarily a result of an increase of $16 thousand in personnel-related costs combined with increases in rent expense of $6 thousand and general lab expenses of $4 thousand.
Our research and development efforts are primarily focused on the development of treatments for Parkinson’s disease, traumatic brain injury, and stroke. These projects are long-term investments that involve developing both new stem cell lines and new differentiation techniques that can provide higher purity populations of functional cells. Research and development expenses are expensed as incurred and are accounted for on a project-by-project basis. However, much of our research has potential applicability to each of our projects.
Other expense, net
Other expense, net for the three months ended September 30, 2026 and 2025 was $28 thousand and $37 thousand, respectively. Other expenses in both periods primarily relate to interest expense on our related party note payable. The decrease of $9 thousand, or 24%, was a result of the payoff of principle balances of $200 thousand and $150 thousand in June of 2025 and February of 2026 combined with the full remaining balance being paid off on September 15, 2026.
Comparison of the Nine Months Ended September 30, 2026 and 2025
The following table summarizes our results of operations for the nine months ended September 30, 2026 and 2025 (in thousands, except percentages):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30, |
|
|
|
2026 |
|
|
2025 |
|
|
$ Change |
|
|
% Change |
|
Product sales |
|
$ |
444 |
|
|
$ |
443 |
|
|
$ |
1 |
|
|
|
0 |
% |
Cost of sales |
|
|
142 |
|
|
|
147 |
|
|
|
(5 |
) |
|
|
-3 |
% |
Profit margin |
|
|
302 |
|
|
|
296 |
|
|
|
6 |
|
|
|
2 |
% |
As a % of revenues |
|
|
68 |
% |
|
|
67 |
% |
|
|
|
|
|
|
General and administrative |
|
|
2,132 |
|
|
|
1,974 |
|
|
|
158 |
|
|
|
8 |
% |
Selling and marketing |
|
|
271 |
|
|
|
295 |
|
|
|
(24 |
) |
|
|
-8 |
% |
Research and development |
|
|
270 |
|
|
|
294 |
|
|
|
(24 |
) |
|
|
-8 |
% |
Other expense |
|
|
(94 |
) |
|
|
(116 |
) |
|
|
22 |
|
|
|
-19 |
% |
Net loss from continuing operations |
|
|
(2,465 |
) |
|
|
(2,383 |
) |
|
|
(82 |
) |
|
|
3 |
% |
Net income from discontinued operations, net of tax |
|
|
23,952 |
|
|
|
2,313 |
|
|
|
21,639 |
|
|
|
|
Net income (loss) |
|
$ |
21,487 |
|
|
$ |
(70 |
) |
|
$ |
21,557 |
|
|
|
-30796 |
% |
As a % of revenues |
|
|
4839 |
% |
|
|
-16 |
% |
|
|
|
|
|
|
Product sales, net
Product sales for the nine months ended September 30, 2026 were $444 thousand compared to $443 thousand for the nine months ended September 30, 2025. This increase of $1 thousand, or 0%, was driven by a decrease in discounts given on product sales with actual product sales decreasing by approximately $34 thousand and discounts increasing by approximately $34 thousand.
Cost of sales
Cost of sales for the nine months ended September 30, 2026 were $142 thousand, compared to $147 thousand for the nine months ended September 30, 2025. The decrease of $5 thousand, or 3%, was due to a decrease in materials combined with a decrease in inventory transactions. These decreases were partially offset by a slight increase in shipping costs.
Profit margins as a percentage of revenue have increased by approximately 1% for the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025. The net increase in gross margins was as a result of less discounts given on product sales.
Cost of sales consists primarily of salaries and benefits associated with employee efforts expended directly on the production of the Company’s products, as well as related direct materials, general laboratory supplies, and the allocation of overhead.
General and administrative expenses
General and administrative expenses for the nine months ended September 30, 2026 were $2,132 thousand, compared to $1,974 thousand for the nine months ended September 30, 2025. The increase of $158 thousand, or 8%, was primarily attributable to approximately $111 thousand related to a patent impairment charge for expired patents. There were also increases in audit fees of $64 thousand, personnel related costs of $63 thousand, general liability insurance costs of $15 thousand, and legal fees of $12 thousand. These increases were partially offset by decreases in D&O insurance of $45 thousand, filing fees of $38 thousand and consulting fees of $24 thousand.
Our general and administrative expenses consist primarily of employee-related expenses including salaries, bonuses, benefits, and stock-based compensation. Other significant costs include facility costs not otherwise included in or allocated to other departments, legal fees not relating to patents and corporate matters, and fees for accounting and consulting services.
Selling and marketing expenses
Selling and marketing expenses for the nine months ended September 30, 2026 were $271 thousand, compared to $295 thousand for the nine months ended September 30, 2025. The decrease of $24 thousand, or 8%, was primarily attributable to a decrease in personnel related costs of approximately $19 thousand, and $5 thousand in website and advertising expenses. These decreases were partially offset by an increase of $3 thousand in dues and subscription costs.
Our selling and marketing expenses consist primarily of employee-related expenses including salaries, bonuses, benefits, and stock-based compensation for our anti-aging cosmetic business. Other significant costs include facility costs not otherwise included in or allocated to other departments, as well as marketing material costs, permits and licenses for ecommerce, and other advertising expenses.
Research and development expenses
Research and development expenses for the nine months ended September 30, 2026 were $270 thousand, compared to $294 thousand for the nine months ended September 30, 2025. The decrease of $24 thousand, or 8%, was a result of a decrease in consulting related costs of $61 thousand combined with a $28 thousand decrease in personnel related costs. These decreases were partially offset by a decrease in the Australian research and development tax credit of approximately $52 thousand combined with an increase of $8 thousand in office expenses and an increase of $3 thousand in general lab expenses.
Our research and development efforts are primarily focused on the development of treatments for Parkinson’s disease, traumatic brain injury, and stroke. These projects are long-term investments that involve developing both new stem cell lines and new differentiation techniques that can provide higher purity populations of functional cells. Research and development expenses are expensed as incurred and are accounted for on a project-by-project basis. However, much of our research has potential applicability to each of our projects.
Other expense, net
Other expense, net for the nine months ended September 30, 2026 and 2025 were $94 thousand and $116 thousand, respectively. Other expenses in both periods primarily relate to interest expense on our related party note payable. The decrease of $22 thousand, or 19%, was as a result of the payoff of principle balances of $200 thousand and $150 thousand in June of 2025 and February of 2026 combined with the full remaining balance being paid off on September 15, 2026.
Liquidity and Capital Resources
We enter into contracts in the normal course of business with various third-party consultants and contract research organizations (“CRO”) for preclinical research, clinical trials and manufacturing activities. These contracts generally provide for termination upon notice. Actual expenses associated with these arrangements may be higher or lower due to various reasons, including but not limited to, progress of our development products and enrollment in clinical trials. Other short-term and long terms commitments that would affect liquidity include lease obligations and potential indemnification obligations under the MIPA. The related party note payable was repaid in full in September 2026, following the sale of LCT which generated $21.7 million in net cash proceeds during the three and nine months ended September 30, 2026. We also recorded $2.6 million in escrow receivable in current assets stemming from the sale of LCT.
As of September 30, 2026, we had an accumulated deficit of approximately $89.6 million and have historically incurred net losses and negative operating cash flows. Substantially all of our operating losses have resulted from the funding of our research and development programs and general and administrative expenses associated with our operations. We incurred net loss from continuing operations of $2,465 thousand and $2,383 thousand for the nine months ended September 30, 2026 and 2025, respectively. As of September 30, 2026, we had cash of approximately $20.0 million, compared to $0.8 million as of December 31, 2025. Our primary use of cash is to continue to fund our research and development programs, while maintaining and growing our revenue generating business. Similarly, we intend to use the net proceeds from the sale of LCT for working capital and general corporate purposes, including the continued clinical development of ISCO's proprietary ISC-hpNSC® therapy for Parkinson’s disease.
Cash Flows
Comparison of the Nine Months Ended September 30, 2026 and 2025
The following table provides information regarding our cash flows for the nine months ended September 30, 2026 and 2025 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30, |
|
|
|
2026 |
|
|
2025 |
|
Net cash used in operating activities |
|
$ |
(136 |
) |
|
$ |
(24 |
) |
Net cash provided by (used in) investing activities |
|
|
21,655 |
|
|
|
(40 |
) |
Net cash used in financing activities |
|
|
(2,479 |
) |
|
|
(200 |
) |
Net increase (decrease) in cash |
|
$ |
19,040 |
|
|
$ |
(264 |
) |
Operating Cash Flows
For the nine months ended September 30, 2026, net cash used in operating activities was $136 thousand, resulting primarily from our net loss from continuing operations of $2,465 thousand and net decreases in cash flows from operating assets and liabilities of $255 thousand, consisting of decreases from payment of accrued interest on related party note payable of $933 thousand, operating lease liabilities of $127 thousand, and inventories, net of $23 thousand. These decreases were partially offset by an increase in cash flow from accounts payable of $701 thousand, accrued liabilities of $69 thousand, and prepaid expenses and other current assets of $58 thousand. In addition, there was a $529 thousand increase pertaining to non-cash adjustments consisting of recurring non-cash expenses, including stock-based compensation, depreciation and amortization expense, non-cash operating lease expense, changes in inventory reserve and interest expense on our related party note payable. The net cash used in operations of $2,191 thousand was offset by $2,055 thousand in cash provided by operating activities for our discontinued operations.
For the nine months ended September 30, 2025, net cash used in operating activities was $24 thousand, attributable to our net loss from continuing operations of $2,383 thousand and net decreases in operating assets and liabilities of $188 thousand, offset by net recurring non-cash adjustments of $477 thousand. The net cash used operations of $2,094 thousand was partially offset by $2,070 thousand in cash provided by operating activities for our discontinued operations
Investing Cash Flows
Net cash provided by investing activities for the nine months ended September 30, 2026 was $21,655 thousand, compared to net cash used in investing activities of $40 thousand for the nine months ended September 30, 2025. The increase in 2026 was primarily the result of the proceeds received from the sale of the LCT business, net of cash divested, of $21,698 thousand. See Note 10 – Discontinued Operations for additional details about the sale of the LCT business and the reconciliation between the $23,088 thousand cash received at closing and the $21,698 thousand proceeds received from the sale of the LCT business, net of cash divested. In addition, purchases of property and equipment decreased by $1 thousand and payments for patent licenses increased by approximately $12 thousand. The remaining difference was attributed to changes in net cash used in investing activities for the discontinued operations.
Financing Cash Flows
Net cash used in financing activities for the nine months ended September 30, 2026 was $2,479 thousand, compared to $200 thousand for the nine months ended September 30, 2025. The change was primarily due to payments on the related party note. In 2026, the remaining principal of $2,500 thousand was paid off compared to $200 thousand in repayments made in 2025. These cash outflows were offset by inflows from proceeds from option exercise.
Funding Requirements
Management continues to evaluate various financing sources and options to raise working capital to help fund our current research and development programs and operations. We will need to obtain significant additional capital from equity and/or debt financings, license arrangements, grants and/or collaborative research arrangements to sustain our operations and develop products. The timing and degree of any future capital requirements will depend on many factors, including:
•the accuracy of the assumptions underlying our estimates for capital needs;
•the extent that revenues from sales of LSC products cover the related costs and provide capital;
•scientific progress in our research and development programs;
•the magnitude and scope of our research and development programs and our ability to establish, enforce, and maintain strategic arrangements for research, development, clinical testing, manufacturing, and marketing;
•our progress with preclinical development and clinical trials;
•the extent to which third party interest in our research and commercial products can be realized through effective partnerships;
•the time and costs involved in obtaining regulatory approvals;
•the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims; and
•the number and type of product candidates that we pursue.
Our failure to raise capital or enter into applicable arrangements when needed would have a negative impact on our financial condition. Additional debt financing may be expensive and require us to pledge all or a substantial portion of its assets. Further, if additional funds are obtained through arrangements with collaborative partners, these arrangements may require us to relinquish rights to some of our technologies, product candidates, or products that we would otherwise seek to develop and commercialize on its own. If sufficient capital is not available, we may be required to delay, reduce the scope of, or eliminate one or more of our product initiatives.
We currently have no revenue generated from our principal operations in therapeutic product development through research and development efforts. There can be no assurance that we will be successful in maintaining our normal operating cash flow and obtaining additional funds.
Critical Accounting Estimates
Our management’s discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States of America and the rules and regulations of the Securities and Exchange Commission. The preparation of these condensed consolidated financial statements requires us to make judgments and estimates that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues, costs, and expenses during the reporting periods.
Our estimates are based on our historical experience, known trends and events, and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities and amount of expense recognized that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We evaluate our estimates and assumptions on an ongoing basis. The effects of material revisions in estimates, if any, will be reflected in the condensed consolidated financial statements prospectively from the date of the change in estimates.
There have been no material changes to our critical accounting policies and estimates during the nine months ended September 30, 2026 from those disclosed in “Part II – Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K.
Recently Issued Accounting Pronouncements
A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 1 – Description of Business, Basis of Presentation, and Summary of Significant Accounting Policies to our condensed consolidated financial statements of this Quarterly Report on Form 10-Q.
Contractual Obligations and Commitments
Other than the repayment in full of the related party note payable in September 2026 and the indemnification obligations we assumed under the MIPA, there have been no material changes to our contractual obligations and commitments outside the ordinary course of business during the nine months ended September 30, 2026 from those disclosed in “Part II – Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
We are a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act, and are not required to provide the information required under this item.
Item 4. Controls and Procedures
Disclosure Controls and Procedures
Evaluation of Disclosure Controls and Procedures
As required by Rule 13a-15(b) and 15d-15(b) under the Exchange Act, the Company, with the participation of management, including our Chief Executive Officer and Principal Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on this evaluation, our Chief Executive Officer and Principal Financial Officer concluded that, at September 30, 2026, our disclosure controls and procedures were effective.
Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Principal Financial Officer, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.
Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
Changes in Internal Control Over Financial Reporting
As a result of the sale and disposal of LCT and its classification as discontinued operations, during the three months ended September 30, 2026 the Company implemented additional controls over the preparation and review of discontinued operations financial information and related disclosures. Additionally, certain controls and processes were modified to reflect the separation of LCT and the transition of responsibilities. These changes were part of our normal financial reporting process enhancements and did not materially affect our internal control over financial reporting.
PART II – OTHER INFORMATION
Item 1. Legal Proceedings
None.
Item 1A. Risk Factors
Other than as set forth below, there have been no material changes to the risk factors disclosed in “Part I – Item 1A. Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 30, 2026.
Risks Related to ISCO Following the Transaction
The Company may be required to indemnify ATCC after the closing for breaches of representations and warranties or covenants under the MIPA.
The Company has agreed to indemnify ATCC for damages arising from, among other things: breaches of the Company’s representations and warranties; breaches of the Company’s covenants and agreements; claims by interest holders of the Company; undisclosed indebtedness; transaction expenses; tax liabilities; fraud or willful misconduct; certain employee-related liabilities; and failures related to intellectual property transfers. The Company’s general representations and warranties survive for nine months following the closing, while Specified Representations survive for four years and Fundamental Representations survive for six years.
If ATCC makes indemnification claims against the Company, the Company may be required to pay substantial damages. While the MIPA provides a deductible of $25 thousand for certain claims, indemnification claims may be satisfied first from the escrow funds and then directly from the Company. No party is liable for damages exceeding the proceeds actually received from the Transaction (other than in the case of Fraud). The Company’s exposure to indemnification obligations could be material and could adversely affect the Company’s financial condition.
Following the Transaction, the Company’s operations have been substantially reduced and the Company is heavily dependent on its remaining business lines.
LCT represented a significant portion of the Company’s business operations, revenue, and assets. As a result of the closing of the Transaction on September 1, 2026, the Company divested the entirety of the membership interests in LCT and no longer derives any revenue, operational support, or strategic benefit from that subsidiary. As a result, the Company’s operations have been substantially reduced and the Company has significantly fewer employees, revenue streams, and assets with which to sustain its continuing business.
The Company’s remaining business lines may not be sufficient to sustain the Company without the development of new revenue sources, strategic acquisitions, or other business initiatives. Investors should be aware that the Company is now a significantly smaller enterprise with greater concentration risk in its remaining operations, and there can be no assurance that those remaining operations will be profitable or sustainable over the long term.
There can be no assurance that the Company will be able to successfully deploy the Transaction proceeds.
At the Closing of the Transaction, the Company received approximately $23.1 million, and $2.6 million of the purchase price was deposited in escrow , with the purchase price remaining subject to customary adjustments for net working capital, closing date cash, and closing date indebtedness, and further subject to the escrow holdbacks described above. Following the closing, the Company will need to identify and evaluate new business opportunities, potential acquisitions, or other uses of capital in order to redeploy the Transaction proceeds in a manner that creates value for stockholders.
There can be no assurance that suitable opportunities will be available, that the Company will be able to consummate any such transactions on favorable terms, or that any deployment of the Transaction proceeds will generate acceptable returns. The Company may face significant competition for attractive acquisition targets or investment opportunities, and the Company’s management team may not have the expertise or resources necessary to execute successfully in new business areas. Any failure to deploy the Transaction proceeds effectively could result in diminished returns for stockholders and a decline in the market price of the Company’s common stock.
The Company may face challenges retaining key employees following the Transaction.
In connection with the closing of the Transaction, the LCT employees transfered to ATCC. The Company’s remaining employees may experience uncertainty regarding their future roles, compensation, and career prospects within a substantially reduced organization. This uncertainty may lead to attrition among key personnel whose skills, experience, and institutional knowledge are critical to the Company’s continuing operations and future strategic initiatives.
The loss of key employees could impair the Company’s ability to execute its remaining business operations, pursue new opportunities, and maintain the relationships necessary for ongoing success. Competition for qualified personnel is intense, and the Company’s reduced size and uncertain strategic outlook following the Transaction may make it more difficult to attract and retain talented employees. Any significant employee departures could have a material adverse effect on the Company’s business, results of operations, and financial condition.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
During the quarter ended September 30, 2026, none of our directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934) adopted, terminated or modified a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).
Item 6. Exhibits
Exhibit Index
|
|
|
Exhibit |
|
Description |
2.1 |
|
Membership Interest Purchase Agreement, dated July 10, 2026, by and among International Stem Cell Corporation, International Stem Cell Corporation, Lifeline Cell Technology, LLC, a California limited liability company, and American Type Culture Collection, Inc. (incorporated by reference to Exhibit 2.1 of the Registrant's Form 8-K filed on July 16, 2026). |
3.1 |
|
Certificate of Incorporation (incorporated by reference to Exhibit 3.4 of the Registrant’s Form 10-SB filed on April 4, 2006). |
3.2 |
|
Certificate of Amendment of Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Registrant’s Preliminary Information Statement on Schedule 14C filed on December 29, 2006). |
3.3 |
|
Certificate of Amendment of Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Registrant’s Form 8-K filed on June 4, 2012). |
3.4 |
|
Certificate of Amendment of Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Registrant’s Form 8-K filed on May 14, 2014). |
3.5 |
|
Certificate of Amendment of Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Registrant’s Form 8-K filed on July 28, 2015). |
3.6 |
|
Certificate of Amendment of Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Registrant’s Form 8-K filed on May 19, 2016). |
3.7 |
|
Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant’s Form 8-K filed on May 6, 2011). |
4.1 |
|
Form of Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 of the Registrant’s Form 10-KSB filed on April 9, 2007). |
4.2 |
|
Certificate of Designation of Series B Preferred Stock (incorporated by reference to Exhibit 4.1 of the Registrant’s Form 8-K filed on May 12, 2008). |
4.3 |
|
Certificate of Designation of Series D Preferred Stock (incorporated by reference to Exhibit 10.2 of the Registrant’s Form 8-K filed on January 5, 2009). |
4.4 |
|
Certificate of Designation of Series G Preferred Stock (incorporated by reference to Exhibit 3.1 of the Registrant’s Form 8-K filed on March 14, 2012). |
4.5 |
|
Certificate of Preferences, Rights and Limitations of Series I-2 Convertible Preferred Stock (incorporated by reference to Exhibit 3.2 of the Registrant’s Form 8-K filed on March 10, 2016). |
10.1 |
|
Form of Support Agreement (incorporated by reference to Exhibit 10.1 of the Registrant's Form 8-K filed on July 16, 2026). |
31.1* |
|
Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer. |
31.2* |
|
Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer. |
32.1* |
|
Section 1350 Certification of Chief Executive Officer. |
32.2* |
|
Section 1350 Certification of Principal Financial Officer. |
101.INS* |
|
Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document |
101.SCH* |
|
Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents |
104* |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
* Filed herewith. Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC; provided, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedules so furnished. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
INTERNATIONAL STEM CELL CORPORATION |
Dated: November 20, 2026 |
|
|
|
|
|
|
By: |
|
/s/ ANDREY SEMECHKIN |
|
|
Name: |
|
Andrey Semechkin |
|
|
Title: |
|
Chief Executive Officer (Principal Executive Officer) |
|
|
|
|
|
|
|
By: |
|
/s/ RUSSELL KERN |
|
|
Name: |
|
Russell Kern |
|
|
Title: |
|
Executive Vice President and Chief Scientific Officer (Principal Financial Officer) |